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Recent technological advances have made it possible to collect multiple types of genomic data on
the same set of subjects. It is of great interest to integrate multiple genomic data types to address
various imperative biological problems, such as to understand the mechanisms of complex diseases,
to predict disease outcomes, and to classify patients into risk groups. Multi-platform genomic data
present unprecedented opportunities to address the above issues but also pose significant statistical
and computation challenges that cannot be adequately tackled using existing methods.
In the first part of the dissertation, we develop a structural equation modeling (SEM) framework
to jointly model the relationships among various types of genomic variables and phenotypes. We
extend the current SEM framework to include semiparametric transformation models for potentially
right-censored time to event. We develop an efficient nonparametric maximum likelihood estimation
approach to estimate the model parameters.
In the second part of the dissertation, we develop a robust score test based on imputed data for
testing the association between a phenotype and a partially missing genomic variable. We impute
the missing values based on a semiparametric model for the genomic variable against other genomic
and non-genomic variables. The proposed test preserves the type I error even when the imputation
model is misspecified. We develop a spline-based method to estimate the semiparametric imputation
model.
In the third part of the dissertation, we develop a method based on statistical boosting and
penalized estimation for the prediction of a potentially right-censored time to event using multiple
types of high-dimensional genomic variables. The proposed method properly accounts for the
differences in size and predictive power across data types. We propose an efficient and stable
computation method that is based on existing algorithms for penalized estimation.
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In all three parts of the dissertation, we evaluate the proposed methods using extensive simulation
studies and demonstrate their advantages over existing methods. We provide applications for each
proposed method to a large-scale multi-platform genomic study, The Cancer Genome Atlas.
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1.1 Integrative Analysis of Genomic Data
In the past two decades, there have been revolutionary advances in high-throughput genome-
profiling technology. As a result, large-scale genomics studies have been able to collect multiple
types of genomic data, including DNA sequences, RNA expressions, and protein expressions, for a
large number of subjects. Such multi-platform genomic data provide opportunities for researchers
to understand gene functions, identify interactions between and within different types of genomic
features, and characterize molecular abnormalities associated with genetic diseases in unprecedented
depth and precision. Integrative statistical methods have been the essential tools for deciphering
these complex multi-platform genomic data.
In this dissertation, we define integrative analysis (of genomic data) broadly as the analysis that
combines multiple types of genomic data under a unified framework. This is sometimes referred to
as “vertical integration”, to distinguish from “horizontal integration” or meta-analysis, which is the
combined analysis of subjects from different studies with the same type of data. Distinct from the
analysis of a single data type, integrative analysis attempts to understand biological mechanisms as
one “integrated system”. The main objectives of integrative analysis include: (a) to characterize the
complex relationships among different types of molecular structures and their relationships with
various phenotypes, (b) to understand the taxonomy of diseases and classify patients into disease
subtypes, and (c) to predict clinical outcomes, such as time to disease progression or death, for
patients (Kristensen et al. 2014).
Integrative analysis can be more effective in addressing the aforementioned issues than the
analysis of a single data type for several reasons. First, any biological mechanism involves the
interplay of various layers of genomic features, and genetic diseases usually involve disruptions at
multiple molecular levels. The activities of one type of genomic feature only reflect a small aspect
of a biological process. For example, the amount and activities of a protein, which play important
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roles in biological processes, are not fully determined by the expression of the corresponding RNA
nor the coding DNA sequence. Therefore, it takes a combination of data types to characterize a
disease and inform accurate phenotype prediction.
Second, the functions of a type of genomic feature can be better understood by evaluating their
interactions with other types of genomic features. Some genomic features, such as alterations of
DNA, affect the phenotypes of interest indirectly through altering other genomic features. Using
multiple genomic data types, we can identify the direct effects of genomic features on a phenotype,
as well as their indirect effects through other genomic features. Also, we can identify spurious
associations between a genomic feature and a phenotype by controlling for the confounding effects
of other genomic features.
Third, information obtained across data types can be aggregated to improve statistical efficiency.
Due to technological limitations and the dynamic nature of biological processes, each type of genomic
data is subject to noise. The presence of multiple data types allows us to confirm or refine the
findings of one data type using other data types. Also, missing data in one data type can be inferred
from the observed data using the known biological associations among them. For example, it has
been shown that a substantial proportion of variation in gene expression can be explained by point
mutations and copy number variations (Stranger et al. 2007).
Despite its advantages, integrative analysis presents unique statistical challenges. First and
foremost, the dimensionality and complexity of the problem increase as more data types are included.
Each genomic data type is high-dimensional, and the relationships among them are complex. As a
result, inclusion of new data types greatly increases the degrees of freedom of the underlying models
and may yield weaker inference. New statistical methods that can handle high dimensionality and
utilize the known biological relationships among the variables are warranted. Also, multi-platform
genomic data typically contain a substantial amount of missing data, because some types of genomic
data are too expensive to be measured for a large number of subjects. We need valid and efficient
methods to handle missing data.
1.2 Types of Genomic Data
In this section, we describe some commonly studied types of genomic data.
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DNA Alteration DNA is the hereditary material in a cell, which contains information for
building and maintaining an organism. Genetic diseases, such as cancer, are driven by abnormal
changes in the DNA sequences, so that the diseased cells no longer perform their normal functions.
DNA alterations that are not inherited from a parent and would not be passed to an offspring are
called somatic DNA alterations. DNA alterations can take several forms, including small mutations,
such as single nucleotide polymorphisms (SNPs) and short insertion or deletion (indels), and other
structural changes, such as copy number variation (CNV).
Methylation Methylation refers to the addition of a methyl group to a DNA molecule. Methyla-
tion changes the activities of the DNA without changing the DNA sequence and thus is a form of
epigenetics. The effect of methylation on gene expression depends on the location; methylations
located at gene promoter regions typically suppress gene expression, while methylations located at
genic regions typically promote gene expression.
Gene Expression and miRNA Expression A gene is a region of DNA that encodes proteins;
there are around 25,000 genes in the human genome. Through the process of transcription,
information of the DNA sequence of a gene is used to produce RNA. One type of RNA, called
messenger RNA (mRNA), is then further translated into protein; gene expression refers to the
expression of mRNA.
A micro RNA (miRNA) is a small non-protein-coding RNA molecule. miRNA serves to regulate
gene expression through RNA silencing and post-transcriptional regulation. miRNAs are mostly
gene expression inhibitors, although there are cases where the expressions of a miRNA and its target
are positively correlated.
RNA expression was traditionally measured using microarray platforms, the first widely used
high-throughput technology. In recent years, microarray platforms were superseded by RNA
sequencing as the major technology to measure RNA expression. Unlike microarray platforms, RNA
sequencing is able to discover novel and rare transcripts and detect small variants.
Protein Proteins perform the basic biological functions of an organism. Changes in protein level
and structure have been shown to play essential roles in tumor development and progression, some
of which are not reflected by genetic changes. The amount and activity of a protein are controlled
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by the expression of the corresponding gene and a set of post-translational modifications (PTM).
One of the most-studied PTM is phosphorylation, which plays a crucial role in regulating protein
activities and interactions among proteins.
A method to measure the expression of proteins and phospho-proteins is reverse phase protein
array (RPPA), a high-throughput antibody-based technique. Because of the inherent difficulty of
replicating and measuring proteins, current technologies only allow the measurement of protein
expressions at a huge cost. As a result, genomic studies have only measured the expression of a
small number of proteins on relatively few subjects.
1.3 The Cancer Genome Atlas
All data analyzed in this dissertation are obtained from The Cancer Genome Atlas (TCGA),
a large public cancer genomics database. The TCGA project was undertaken by the National
Institutes of Health (NIH), jointly led by the National Cancer Institute (NCI) and the National
Human Genome Research Institute (NHGRI). The main goal of the project is to discover and
characterize all key genomic alterations in the major types and subtypes of cancer. Since 2005,
TCGA has generated detailed molecular data for over 11,000 cancer samples with 33 types of
cancer. Subjects were measured for multiple types of genomic data, including somatic mutation,
copy number variation, methylation, and expressions of miRNA, mRNA, and proteins, using various
methods, including microarrays and next-generation sequencing platforms. Figure 1.1 shows the









Figure 1.1. Types of Data Measured in TCGA and Their Potential Relationships.
4
1.4 Existing Statistical Methods for Integrative Analysis
Methods for integrative analysis vary according the type of biological question being addressed.
We classify methods for integrative analysis broadly into those that concern (a) the estimation of
the relationships among genomic variables and phenotypes, (b) the test of the effects of genomic
variables on phenotypes, and (c) the prediction of phenotypes using (high-dimensional) genomic
variables.
1.4.1 Modeling Relationships Among Multiple Types of Variables
A popular approach for simultaneously modeling the relationships among multiple variables,
both latent and observed, is structural equation modeling (SEM). SEM is traditionally used in
the social sciences and psychology research but has also found applications in genomics in recent
years. For example, Li et al. (2006) proposed an SEM to capture the association among genetic
loci and multiple phenotypes. Lee et al. (2007) proposed an SEM to study the interaction among
genes, whose activities were represented by latent variables and are manifested by SNP data. Nock
et al. (2007) and Nock et al. (2009) used SEM to study the effects of different genes on rheumatoid
arthritis and the Metabolic Syndrome, respectively.
A related approach for jointly modeling different types of genomic variables is PARADIGM
(PAthway Recognition Algorithm using Data Integration on Genomic Models) (Vaske et al. 2010).
In this approach, quantities that represent observable data, such as copy number variation, gene
expression, and protein abundance, and abstract processes, such as DNA damage and apoptosis, are
represented by vertices on a graph. The vertices are linked by edges that represent the associations
among the quantities. The graph is constructed based on prior biological knowledge. Using an
Expectation-Maximization (EM) algorithm, the activity of each unobserved quantity can be inferred.
The authors showed that the inferred activity can be used to effectively classify patients into
subtypes.
A series of papers by Huang and his collaborators (Huang 2014; 2015; Huang et al. 2014; 2015;
2016) considered the joint analysis of multiple genomic variables and a phenotype, which may
be binary, continuous, and censored. Under a mediation analysis framework, the authors were
able to identify the direct and indirect effects of genomic variables on other genomic variables and
phenotypes.
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1.4.2 Testing the Effects of Multiple Types of Variables on Phenotypes
A primary interest in genomics studies is to test the association between genomic variables and
phenotypes of interest. For illustration, let G denote a vector of SNP variables from a particular
gene or genetic region, S denote a vector of genomic variables of the gene that are regulated by
G, such as gene expression and protein expression, Z denote a vector of covariates, and Y denote
the phenotype of interest. We are interested in testing the association between Y and individual
elements ofG or the overall activity of the gene. We classify approaches that incorporate information
from S into the following categories: (a) methods that combine test results from multiple platforms;
(b) methods that incorporate multiple platforms into a single regression framework; (c) methods
that separately test the direct and indirect effects of the genetic variants; and (d) methods that
incorporate the association between the genetic variants and other platforms.
The first group of approaches combines test results from multiple platforms. For complex
phenotypes, the associations between individual genetic variants and the phenotypes are typically
weak. If the variables derived from the same genetic region from different platforms exhibit similar
association patterns with a phenotype, then one can improve power by combining the test results
from the platforms with the results from the genetic variants. Hamid et al. (2009) reviewed methods
that combine the effect sizes or p-values from individual platforms. Xiong et al. (2012) developed a
method for combining the effects of SNPs and gene expressions, estimated by separate regression
analyses, into the effects of the corresponding genes or pathways.
The second group of approaches considers multiple platforms under a single regression framework.
Tyekucheva et al. (2011) proposed to fit a standard regression model for a phenotype on genomic
variables of a gene from different platforms. A score is given to each gene according to the significance
of the joint test of all regression parameters, and the scores from multiple genes are combined using
a similar approach as Xiong et al. (2012) into pathway-level association scores. Huang (2014; 2015);
Huang et al. (2014; 2015; 2016) considered joint tests of the effects of SNPs and other genomic
variables. Instead of adopting a traditional test with the degrees of freedom equal to the number of
coefficients being tested, a variance component test was adopted. This approach is powerful if the
SNP effects are uniformly spread over the SNPs and the effect of an individual SNP is weak.
The third group of approaches separately tests the direct effect of G on Y or the indirect effect
of G on Y through S. Typically, the effects of SNPs are mediated through other genomic variables,
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such that the direct effects of SNPs are weaker than the indirect effects. As a result, it may be more
powerful to isolate and test the indirect effects than testing the marginal effects of the SNPs. Zhao
et al. (2014) proposed to test the indirect effect of G by a two-step approach. In the first step, we
estimate the function of S through which S affects Y . In the second step, we test the association
between G and the function of S identified in the first step; the procedure can be understood as
testing the effect of G on the part of Y affected by S. This test is powerful when the total effect of
G mainly consists of the indirect effect. Huang and Pan (2015) proposed to test the indirect effect
of individual components of G through the expression of multiple genes using a variance component
test. If the indirect effects through the expression of different genes are of different signs, then the
variance component test is more powerful than testing the marginal effects.
Finally, the last group of approaches utilizes the associations among the genomic variables to
improve power. One simple method is to screen components of G based on their association with
S. Because functional SNPs are expected to perturb the expression of genes, SNPs that are not
associated with the expression of any gene are likely to be not related to the phenotypes of interest.
By screening out the SNPs with very weak or no association with S, the burden on multiple-testing
correction is lightened, and the overall power is increased. He et al. (2013) developed a Bayesian
method, named Sherlock, to search for gene-phenotype associations. The presence of associations
between both G and S and G and Y provides positive evidence for gene-phenotype association,
while the presence of association between G and S along with the absence of association between
G and Y provide negative evidence for gene-phenotype association.
1.4.3 Phenotype Prediction Using Multiple Types of High-Dimensional Variables
A naïve approach to combine information from multiple genomic platforms is to concatenate
data matrices from the platforms and perform standard analyses on the combined data. For example,
one may perform generic variable selection procedures, such as LASSO (Tibshirani 1996) and elastic
net (Zou and Hastie 2005), on the set of predictors from all genomic platforms. However, this
approach does not make use of the information that the predictors come from different platforms
and are inherently different. We discuss more sophisticated approaches, which can be classified
into the following two categories: (a) methods that account for the differences in predictive power
of different platforms; and (b) methods that incorporate the associations among variables from
different platforms.
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The first group of approaches assigns weights to the platforms according to their importance.
Lanckriet et al. (2004) adopted a kernel support vector machine (SVM) approach for classification.
SVM is a supervised classification procedure that divides the feature space into two compartments,
such that observations with different outcomes belong to different compartments and are as separated
as possible. The classification rule is computed by solving an optimization problem that involves the
phenotype and the distance between each pair of observations in the feature space. The innovation
of Lanckriet et al. (2004) is to define the distance between the genomic profiles of two subjects, i.e.,
the distance in the feature space, by a weighted sum of the distances along the spaces of the genomic
platforms. The weights, which are calculated based on the data, reflect the relative importance of the
genomic platforms. The special case of zero weight represents that the corresponding platform plays
no role in determining the distance between two subjects and thus not affecting the classification
rule. Similar approaches were proposed by Daemen et al. (2009) and Seoane et al. (2014) for more
complex settings.
The second group of approaches incorporates the associations among genomic platforms. Wang
et al. (2013) proposed to decompose gene expression into a component that is regulated by methyla-
tion and a component that is not regulated by other variables, where the two components affect the
phenotype differently. The Bayesian LASSO was proposed to estimate the effect of each component
of the gene expression variables. The advantage of such a decomposition is twofold. First, the
gene expression variable can be “denoised”, i.e., the effect of the component that is not regulated,
which may represent noise, can be set to zero. Second, methylation can be limited to have no direct
effect on the phenotype but can have indirect effects through gene expression. This would yield
more biologically interpretable results. This approach was extended by Jennings et al. (2013) and
Denis and Tadesse (2016) to include more genomic platforms by further decomposition of genomic
variables and inclusion of more levels of regulation. Zhu et al. (2016) considered a similar two-step
approach. Let S and G be two types of genomic variables, where S is regulated by G. First, some
low-dimensional linear functions of S that are regulated by G are identified. Then, the phenotype
is regressed on the functions of S identified in the first step along with other components of S and
G. In this approach, overlapped information between G and S can be removed, and S is allowed to
have more “direct” effect on the phenotype.
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1.5 Outline of Dissertation
In this dissertation, we focus on methods for identifying the associations between genomic
variables and phenotypes of interest in integrative genomics studies, with special attention to
right-censored time to event. In particular, in the following three chapters, we study the problems
of estimation, hypothesis testing, and variable selection in high-dimensional settings, respectively.
Future work on variable selection is discussed in the last chapter. The proposed methodology in
each chapter is especially designed for integrative analysis, such that they take into account the
differences across and relationships among different data types.
In Chapter 2, we consider a semiparametric structural equation modeling framework to incorpo-
rate the biological relationships among different types of genomic data and phenotypes, including
right-censored time to event. We include latent variables to accommodate measurement error of
the genomic variables. We propose a semiparametric approach to efficiently estimate the model
parameters.
In Chapter 3, we propose a hypothesis test for the association between a phenotype and a
genomic variable with partially missing values. We propose a semiparametric robust approach to
impute the missing values using other observed variables. Under general missing-data mechanisms,
the type I error of the proposed test is preserved, even when the imputation model is misspecified.
In Chapter 4, we consider a high-dimensional regression model with multiple types of genomic
variables as predictors. We propose a method based on statistical boosting and penalized estimation,
which accounts for the differences among the different types of variables, for variable selection and
phenotype prediction. We develop an algorithm based on the coordinate-descent method for the
computation of the solution.
In Chapter 5, we discuss a future direction of research and present some preliminary results.
We consider a variable selection problem with partially missing high-dimensional multi-platform
genomic data. We propose a joint latent variable model for different types of genomic variables to
infer missing values from observed data. We develop a computationally efficient penalization EM
algorithm for variable selection.
9
CHAPTER 2
SEMIPARAMETRIC STRUCTURAL EQUATION MODELING WITH
CENSORED DATA
2.1 Introduction
Structural equation modeling (SEM) is a very general and powerful approach to capture complex
relationships among multiple factors, both observed and latent (Bollen 1989). A typical SEM
framework consists of a structural model that connects latent variables and a measurement model
that relates latent variables to observed variables. SEM is extremely popular in the social sciences and
psychology, where unmeasured quantities and psychological constructs, such as human intelligence
and creativity, can be related to and investigated through observed data. The text of Bollen (1989)
has been cited more than 20,000 times. Recently, SEM has gained popularity in medical and public
health research (Dahly et al. 2009; Naliboff et al. 2012).
Our interest in SEM was motivated by its potential application to integrative analysis in genomic
studies. Recent technological advances have made it possible to collect different types of genomic
data, including DNA copy number, SNP genotype, DNA methylation level, and expression levels
of mRNA, microRNA, and protein, on a large number of subjects. There is a growing interest in
integrating these genomic platforms so as to understand their biological relationships and predict
disease progression and death, which are considered potentially censored survival times (The Cancer
Genome Atlas (TCGA); https://tcga-data.nci.nih.gov/tcga/).
SEM with discrete survival times has been studied by Rabe-Hesketh et al. (2001; 2004), Muthén
and Masyn (2005), and Moustaki and Steele (2005). For continuous survival time, Larsen (2004;
2005) adopted the proportional hazards model (Cox 1972) with a single latent variable to capture
the association between the survival time and other observed variables; Asparouhov et al. (2006)
considered a more general formulation of the association among the latent and observed variables.
SEM with the Cox proportional hazards model for the survival component has been adopted for more
complex settings, such as multivariate survival times (Stoolmiller and Snyder 2006) and competing
risks (Stoolmiller and Snyder 2013). A popular software program, Mplus (Muthén and Muthén
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1998–2015), has implemented SEM with survival data under the proportional hazards model. The
estimation of the nonparametric baseline hazard function is based on piecewise-constant splines,
and no theoretical justification is available. In fact, the standard error estimator for the baseline
hazard function is incorrect.
In this chapter, we propose a general SEM framework that includes a semiparametric component
of the measurement model for potentially censored survival times. Specifically, we formulate the
effects of latent and observed covariates on survival times through a broad class of semiparametric
transformation models that includes the proportional hazards model as a special case. The observed
covariates may include manifest variables that depend on latent variables. We study nonparametric
maximum likelihood estimation (NPMLE), under which the cumulative hazard functions are
estimated by step functions with jumps at observed survival times.
The proposed SEM is reminiscent of joint modeling for survival and longitudinal data (Henderson
et al. 2000; Tsiatis and Davidian 2004). With the latter, the observed longitudinal variables are
considered error-prone measurements of some underlying latent variables, but the measurements
themselves are not causal determinants of the survival time. By contrast, our SEM framework allows
latent variables to have direct effects on survival times, as well as indirect effects through other
manifest variables. In addition, our framework accommodates much more complex relationships
among latent variables.
A major challenge in our theoretical development is model identifiability. Even for an SEM
with normally distributed variables, no single set of conditions exists that is both necessary and
sufficient for model identifiability. Methods that deal with special cases of the normal SEM were
proposed by Bollen (1989), Reilly and O’Brien (1996), Vicard (2000), and Bollen and Davis (2009),
among others. Most of the methods are based on the fact that identifiability can be established by
solving the equations relating the first two model-implied moments to the sample moments. This
approach is not directly applicable to models with nonparametric components, as infinite-dimensional
parameters cannot be identified through a finite number of equations. Because the proportional
hazards structure results in a likelihood function that takes the form of a Laplace transform, however,
we are able to develop sufficient conditions under which the identifiability of a semiparametric SEM
can be established by inspecting simpler parametric models.
Another theoretical challenge is the invertibility of the information operator. For the information
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operator to be invertible, we require that the score statistic along any non-trivial submodel is non-
zero. As in the case of model identifiability, general conditions for the invertibility of the information
operator for semiparametric models do not exist. In the existing work involving latent variables for
survival times (Kosorok et al. 2004; Zeng and Lin 2010), verifying the invertibility of the information
operator involves inspecting the local behavior of the score statistic around the zero survival time.
This approach does not make full use of the variability of the score statistic contributed by the
survival times and cannot deal with the proposed general modeling framework. We show that the
invertibility of the information operator can be verified by inspecting the parametric components of
the SEM under some mild conditions in the survival model.
The rest of this chapter is structured as follows. In Chapter 2.2, we formulate the model and
describe our approach to establish model identifiability. In Chapter 2.3, we discuss the numerical
implementation of the NPMLE. In Chapter 2.4, we present theoretical results for model identifiability
and describe the asymptotic properties of the estimators. In Chapter 2.5, we report the results from
simulation studies. In Chapter 2.6, we provide an application to the TCGA data, which motivated
this work. We make some concluding remarks in Chapter 2.7 and relegate theoretical proofs to
Chapter 2.8.
2.2 Basic Framework
2.2.1 Model and Likelihood
Let η denote a q-vector of latent variables, Y denote an r-vector of uncensored manifest variables,
(T1, . . . , TK) denote K potentially censored survival times, and W and Z denote two vectors of
observed covariates. Without loss of generality, assume that the support of the covariates includes
zero. We specify the conditional distributions of η given Z, Y given Z and η, and Tk given W , Z,
Y , and η as follows:
η | Z ∼ Fη (· | Z;ν) , (2.1)
Y | (Z,η) ∼ FY (· | Z,η;ψ) , (2.2)





, k = 1, . . . ,K, (2.3)
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where Fη(· | Z,ν) denotes a q-variate normal distribution function indexed by a parameter vector
ν, FY (· | Z,η;ψ) denotes an r-variate parametric distribution function indexed by a parameter
vector ψ, ΛTk is the cumulative hazard function of Tk given (W ,Z,Y ,η), Gk is a known increasing
function, Λk is an unspecified positive increasing function with Λk(0) = 0, and (ϑk,βk,αk,φk) are
unknown regression parameters.
Model (2.1) is the structural model of the latent variables. Model (2.2) is the measurement
model of Y . We assume that Y and η are independent of W given Z. Models (2.1) and (2.2)
represent the existing SEM framework with Y not restricted to be normally distributed. Equation
(2.3) includes the proportional hazards and proportional odds models as special cases with the
choices of Gk (x) = x and Gk (x) = log (1 + x), respectively. The proportional hazards model has
been considered in the literature.
The survival time Tk is subject to right censoring by Ck. It is assumed that (C1, . . . , CK) are
independent of (T1, . . . , TK) and η conditional on Y , Z, and W . Define T̃k = min(Tk, Ck) and
∆k = I(Tk ≤ Ck), where I(·) is the indicator function. For a sample of size n, the observed data
consist of Oi ≡ (T̃1i, . . . T̃Ki,∆1i, . . . ,∆Ki,Y i,Zi,W i) (i = 1, . . . , n).
Let θ denote the collection of all Euclidean parameters, and write A = (Λ1, . . . ,ΛK). The

























































/dx for any function f , λk = Λ′k, fY = F ′Y , and fη = F ′η. The NPMLE is
defined to be the maximizer of Ln(θ,A), in which Λk is treated as a step function with jumps at
T̃ki with ∆ki = 1 (i = 1, . . . , n).
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2.2.2 Model Identifiability
We describe our approach to establish model identifiability in this section and defer the technical
details to Chapter 2.4. The identifiability results can be summarized by two simple rules. Suppose
that we have arranged the survival times such that for some 0 ≤ K1 ≤ min(q,K), each of
(T1, . . . , TK1) regresses on and only on one latent variable and a set of covariates that are independent
of the latent variables. (We allow K1 = 0 if no survival time satisfies the given conditions, in which
case Rule 1 below is vacuous.) We call an observed variable X an indicator of a latent variable η if
X follows a generalized linear model with η as a covariate and is independent of all other manifest
variables and survival times conditional on η. We have the following rules:
Rule 1. The latent variables attached to (T1, . . . , TK1) can be treated as observed if each of
(T1, . . . , TK1) depends on at least one observed covariate.
Rule 2. If each latent variable has a separate continuous indicator and the distributions of the
latent variables and the indicators are identifiable, then the whole model is identifiable.
To illustrate the usefulness of the two identifiability rules, we present two examples.
Example 2.1. Consider the model depicted in Figure 2.1. In the model, Y1, Y2, and Y3 are
conditionally independent normal manifest variables of η, and T is a survival time that follows the
proportional hazards model with covariate η. Assume that the regression parameter of Y1 on η
is fixed to be one, E(η) = 0, and the regression parameters of η in the models of Y2 and Y3 are
non-zero.
Figure 2.1. The First Example of SEM to Illustrate the Identifiability Rules. The SEM consists of
one latent variable, one survival time, and three conditionally independent normal manifest variables.
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The above model is similar to the joint model for survival and longitudinal variables. By Bollen
(1989)’s three-indicator rule, the model of (Y1, Y2, Y3, η) is identifiable. With Y1 serving as an
indicator of η, Rule 2 implies that the remaining parameters are identifiable. Note that Rule 1 is
not applicable in this case because T does not depend on an independent covariate. In fact, the
model is not identifiable without (Y1, Y2, Y3) because the scale of the baseline hazard function and
the variance of η cannot be separated.
Example 2.2. Consider the model depicted on the left-hand side of Figure 2.2. In the model, Y1,
Y2, and Y3 are conditionally independent normal manifest variables of η2, T1 is a survival time
that follows the proportional hazards model with covariates W and η1, and T2 is a survival time
that follows the proportional hazards model with covariates η1 and η2. Assume that W and Z are
non-constant and linearly independent, the regression parameters for the latent variables in the
models of T1 and Y1 are fixed to be one, E(η1) = E(η2) = 0, and the regression parameters of W in
the model of T1 and η2 in the models of Y2 and Y3 are non-zero.
Figure 2.2. The Second Example of SEM to Illustrate the Identifiability Rules. The left panel is an
SEM that consists of two latent variables, two observed covariates, two survival times, and three
conditionally independent normal manifest variables. The right panel is an intermediate step in
identifying the SEM on the left.
First, we use T1 to help identify the latent variable distributions. By Rule 1, η1 can be treated
as observed when identifying the model. The problem thus reduces to identifying the model shown
on the right-hand side of Figure 2.2. The model can then be shown identifiable by the arguments
used in Example 2.1.
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2.3 Computation of the NPMLE
In this section, we use Z to denote both W and Z with βk (k = 1, . . . ,K) as the corresponding
vector of regression parameters. Application of a transformation Gk can be viewed as inclusion
of an extra latent variable log sk in the regression equation, where sk is a random variable with
density gk such that Gk(x) = − log
´∞
0 e
−xtgk(t) dt. We adopt the Expectation-Maximization (EM)
algorithm (Dempster et al. 1977) by treating the latent variables, including those introduced by the
transformations, as missing data. We perform occasional Newton-Raphson steps to speed up the
convergence.
In the combined algorithm, either an EM step or a Newton-Raphson step is performed at each
iteration. To avoid confusion, we call the latter an outer Newton-Raphson step. For an EM step,
note that the conditional expectation for any function ϕ of (ηi, si) ≡ (ηi, s1i, . . . , sKi) given the
observed data is






























g (s) dη ds1 · · · dsK ,
where Λk {t} is the jump size of the step function Λk at t, s = (s1, . . . , sK), g (s) =
∏K
k=1 gk(sk),
and C equals the above integral evaluated at ϕ(·, ·) = 1. We use the Gauss-Hermite quadrature to
approximate the integrals. To reduce the number of abscissas, we adopt an adaptive quadrature
approach (Liu and Pierce 1994). Denote the approximation of the conditional expectation as
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where (βk,αk,φk) are evaluated at the current estimates. In addition, we update the remaining
















If a closed-form solution is not available, then we apply the one-step Newton-Raphson algorithm to
the above expression instead. The above algorithm can be generalized to the case where components
of Y i that do not appear in the model of the survival times are missing at random for some subjects.
In this case, we simply drop the corresponding fY terms in the evaluation of Ê and the complete-data
log-likelihood.
For an outer Newton-Raphson step, we apply the one-step Newton-Raphson algorithm directly
to the logarithm of Ln(θ,A) given in (2.4) using a similar adaptive quadrature approximation. At
the current estimates, the first derivative of logLn(θ,A), i.e., the score statistic, is the same as
the first derivative of the expected complete-data log-likelihood. The Hessian matrix used in the
Newton-Raphson algorithm can be obtained by Louis (1982)’s formula.
To determine whether an EM step or an outer Newton-Raphson step is to be performed, we
keep track of the difference in the log-likelihood at the previous iteration, either an EM or an
outer Newton-Raphson step, and the difference at the previous outer Newton-Raphson step. For
each iteration, if the log-likelihood difference at the previous step is too small relative to that
at the previous outer Newton-Raphson step, then an outer Newton-Raphson step is performed;
otherwise, an EM step is performed. Upon convergence, Louis (1982)’s formula is used to obtain
the information matrix for the estimation of the standard errors.
The reason that we use a combination of the EM and Newton-Raphson algorithms instead
of the Newton-Raphson algorithm alone is two-fold. First, EM steps are more stable, which is
important, especially in early iterations. Second, in the estimation of the survival model under the
EM algorithm, the regression parameters can be obtained by maximizing the partial-likelihood-type
function, and the estimators of the baseline hazard functions take the form of the Breslow estimator.





As discussed in Chapter 2.2, we set aside K1 survival times, T1, . . . , TK1 , that are used to identify
the distribution of the underlying latent variables. We assume that span(φ1, . . . ,φK1) = R
K1 . We
can choose the K1 survival times such that each is associated with a few, preferably only one,
latent variables. (K1 is allowed to be 0, in which case we rely solely on the manifest variable Y
to identity the latent variable distribution.) Without loss of generality, we assume that φk = ek
(k = 1, . . . ,K1), where ek is a q-vector with 1 at the kth position and 0 elsewhere. This assumption
can be satisfied by applying a linear transformation to the latent variables. Effectively, we fix the
scale of the first K1 latent variables, as is common when establishing model identifiability for SEM.
We partition η into (η1,η2), where η1 ≡ (η11, . . . , η1K1) consists of the first K1 components of η.
We consider the following identifiability conditions. For the “baseline” hazard functions
(Λ1, . . . ,ΛK), we only require identifiability on [0, τ ], where τ denotes the study duration.
(C1) If (1,WT,ZT,Y T)Tc = 0 almost surely for some vector c of appropriate dimension, then
c = 0. For k = 1, . . . ,K, λk is continuous and strictly positive on [0, τ ], and there exists a




mk is the Lebesgue measure or the counting measure at 1.
(C2) For k = 1, . . . ,K1, E(Y Tαk | Z = 0) = 0, and E(η | Z = 0) = 0. Also, for any vectors c1
and c2 of appropriate dimensions, E(eY
Tc1+ηTc2 | Z) is finite almost surely.
(C3) For k = 1, . . . ,K1, ϑk is non-zero, and αk and βk are zero.
(C4) Consider two sets of parameters (ψ,ν) and (ψ̃, ν̃). Let fY,η1 be the density of (Y ,η1) given
Z. Then, fY,η1(Y ,η1 | Z;ψ,ν) = fY,η1(Y ,η1 | Z; ψ̃, ν̃) for all Z, Y , and η1 implies that
ψ = ψ̃ and ν = ν̃.
(C5) Let (Y +,η+1 ) be the components of (Y ,η1) that appear in the regression of Tk for some
k = K1 + 1, . . . ,K, and let (Y −,η−1 ) be the remaining components. Let Fη2|Y,η1 be the
distribution function of η2 given (Z,Y ,η1) with (Y −,η−1 ) treated as a parameter vector.
Then, η2 is complete sufficient in {Fη2|Y,η1(· | Z,Y ,η1) : Z = z0,Y
+ = y0,η+1 = η10} for
any fixed z0, y0, and η10.
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Remark 2.1. Condition (C1) pertains to basic requirements on the covariates, the baseline hazard
functions, and the transformation functions such that the survival model with observed covariates
is identifiable. If mk is a point mass at 1, then Gk is simply the identity function. Condition
(C2) fixes the location parameters of the latent variables and the manifest variables that appear
in the regression models of the first K1 survival times. Condition (C3) requires that the first
K1 survival times depend only on their corresponding latent variable and W . The presence of a
covariate besides the latent variable is necessary for distinguishing the contributions of the baseline
hazard function and the latent variable to the distribution of a survival time that follows a mixture
distribution. Condition (C4) requires that the model with observed (Y ,η1) is identifiable. Condition
(C5) requires that η2 is complete sufficient conditional on (Y ,η1), where components of (Y ,η1)
that do not appear in the regression of Tk (k = K1 + 1, . . . ,K) are treated as parameters, and the
rest are held fixed. Conditions (C2) and (C3) are vacuous if K1 = 0, and condition (C5) is vacuous
if K1 = K.
We have the following identifiability result.
Theorem 2.1. Under conditions (C1)-(C5), the model specified by (2.1)-(2.3) is identifiable.
Remark 2.2. The condition that αk and βk are zero for k = 1, . . . ,K1 separates the first K1 survival
times from the remaining observed variables that are associated with the latent variables. This
condition is used to simplify the presentation of the identifiability conditions. In the proof of
Theorem 2.1, we consider generalized versions of conditions (C3)-(C5), where αk and βk are allowed
to be non-zero.
Remark 2.3. Theorem 2.1 implies that the distribution of the latent variable underlying a given
survival time can be completely identified if the survival time only regresses on the latent variable
and a set of independent covariates. Thus, the survival times make it easy to identify the model, as
only a single survival time is enough to identify an underlying latent variable. By contrast, this
property does not hold for normal random variables.
Remark 2.4. The derivation of model identifiability from condition (C5) utilizes the property of
complete sufficient statistics. The derivation is applicable to general latent variable models; the
general result is given by Lemma 2.1 in Chapter 2.8. Lemma 2.1 allows for the establishment of
model identifiability by inspecting just a part of the model. It includes Reilly and O’Brien (1996)’s
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side-by-side rule, which states that the loadings of an observed variable on any number of latent
variables are identifiable if each of the latent variables is attached to a separate independent observed
variable whose distribution is identifiable, as a special case.
2.4.2 Asymptotic Properties
Let d be the dimension of θ, θ0 denote the true value of θ, and Λ0k denote the true value of Λk
(k = 1, . . . ,K). We impose the following conditions.
(D1) The parameter θ0 lies in the interior of a compact set Θ ⊂ Rd, and the function Λ0k is
continuously differentiable with λ0k(t) ≡ Λ′0k(t) > 0 on [0, τ ] for each k = 1, . . . ,K.
(D2) With probability one, P (T̃ki = τ |W ,Z) > δ0 (k = 1, . . . ,K) for some fixed δ0 > 0.
(D3) Consider any fixed Z and (ψ,ν) ∈ Θψν , where Θψν consists of the (ψ,ν)-component of every
θ ∈ Θ. For any constant a1 > 0 and δ = 0, 1,
E
{ˆ
ea1(1+|Y |+|η|)fY (Y | Z,η;ψ)δ fη (η | Z;ν) dη
}
<∞.




fY (Y | Z,η;ψ)





fη (η | Z;ν)
fη (η | Z;ν)
∣∣∣∣∣ ≤ ea2(1+|Y |+|η|).
In addition, for some positive constants Mj and cj , N j ∈ Rr, and ϕ1 ∈ `∞(Rr),
e
∑q




j Y bj+cjb2j )ϕ1 (Y ) fY (Y | Z,η;ψ) fη (η | Z;ν) ≤ e
∑q
j=1 Mj |bj |,
where b = S (η) for some one-to-one linear transformation S.
(D4) The function Gk is four-times differentiable, Gk (0) = 0, and K1k (1 + x)−κ1k ≤ G′k (x) ≤
K2k (1 + x)κ2k for some positive constants κ1k, κ2k, K1k, and K2k. Also, Gk(x)/xρk → Mk
or Gk(x)/ log(x) → Mk as x → ∞ for some positive constants Mk and ρk. In addition,
exp {−Gk(x)} ≤ µk (1 + x)−κ3k for some µk and κ3k > κ2k + 1. Furthermore, for some rk,
sup
x≥0
∣∣G′′k (x) ∣∣+ ∣∣G(3)k (x) ∣∣+ ∣∣G(4)k (x) ∣∣
G′k(x) (1 + x)
rk <∞,
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where G′′k and G
(j)
k denote the second and jth derivatives of Gk, respectively.
(D5) Let (Z(k),Y (k)) be the components of (Z,Y ) that appear in the regression of Tk (k =















Y ,η1 | Z;ψ,ν
)
is equal to 0 for all Z, Y , and η1, then h1 = 0, h2k = 0, and h3k = 0 for k = 1, . . . ,K1,
where fY,η1 is defined in condition (C4).
Remark 2.5. Conditions (D1)-(D4) are similar to the conditions of Zeng and Lin (2010) for joint
modeling of longitudinal and survival data. Extra conditions are imposed on the transformations
and the distributions of Y and η to accommodate the presence of unbounded covariate Y in the
survival model. Condition (D5) is for the invertibility of the information operator. If αk = 0 and
βk = 0 for k = 1, . . . ,K1, then condition (D5) simply requires that the information matrix of the
model for (Y ,η1) is invertible. This is parallel to condition (C4) for identifiability.
Remark 2.6. The conditions for identifiability and the invertibility of the information operator
(C1)-(C5), and (D5) differ significantly from the corresponding conditions (C5) and (C7) of Zeng
and Lin (2010). The latter are stated under very general settings, but they are hard to verify for
specific models, especially under our SEM framework. By contrast, our conditions are easier to
verify and have intuitive interpretations. For the model in Example 2.1, (D5) simply requires that
the model of (Y1, Y2, Y3, η1) given Z has a non-zero score statistic, which clearly holds.
Let A0 = (Λ01, . . . ,Λ0K) and (θ̂, Â) be the NPMLE of (θ,A). Also, let V = {v ∈ Rd, |v| ≤ 1}
and Q = {h (t) : ‖h (t)‖V [0,τ ] ≤ 1} with ‖·‖V [0,τ ] being the total variation norm on [0, τ ]. We consider
(θ̂ − θ0, Â − A0) as a random element in l∞(V ×QK) with
(
θ̂ − θ0, Â − A0
)














We have the following results.
Theorem 2.2. Under conditions (C1)-(C5) and (D1)-(D5),
1. |θ̂ − θ0|+
∑K
k=1 supt∈[0,τ ]
∣∣Λ̂k(t)− Λ0k(t)∣∣→a.s. 0; and
21
2. n1/2(θ̂ − θ0, Â − A0) →d G in l∞(V × QK), where G is a continuous zero-mean Gaussian
process. Furthermore, the limiting covariance matrix of n1/2(θ̂−θ0) attains the semiparametric
efficiency bound.
Remark 2.7. The proof of Theorem 2.2 relies on the Donsker properties of certain classes of functions.
It is more challenging to establish the Donsker results in our setting than in previous settings (e.g.,
Kosorok et al. (2004) and Zeng and Lin (2010)) because the likelihood function of the proposed
model may contain the unbounded variable Y .
Remark 2.8. A key step in proving the asymptotic normality of the NPMLE is to show that the
information operator is invertible. The result is given by Lemma 2.2 in Chapter 2.8, which states
that condition (D5), together with conditions (C1)-(C3), and (C5), implies that the information
operator of the model is invertible. With this result, we can verify the invertibility of the information
operator of the semiparametric model by inspecting the parametric part of the model that contains
the observed and latent variables. For the frailty models in Kosorok et al. (2004), verification of
the invertibility of the information operator involves inspection of the local behavior of the score
around T = 0. However, that approach is limited to frailty distributions that are indexed by a
one-dimensional parameter and is not directly applicable to cases with more complex latent variable
distributions such as those in our setting.
2.5 Simulation Studies
We considered a model with covariates Z = (Z1, Z2)T, two latent variables (η1, η2), observed
continuous variables (Y1, . . . , Y5), observed binary variables (Y6, Y7), and a survival time T . Their
distributions are given by
ΛT (t | Z, Y6, Y7, η2) = G{Λ0(t) exp(XTTβT + φT η2)}, XT = (Z1, Z2, Y6, Y7)T,
logit {P(Y6 = 1 | Z, η2)} = XTY6βY6 + φY6η2, XY6 = (1, Z1, Z2)
T,
logit {P(Y7 = 1 | Z, Y6, η2)} = XTY7βY7 + φY7η2, XY7 = (1, Z1, Z2, Y6)
T,
Yj | η1 ∼ N(βYj + φYjη1, σ2Yj ), j = 1, 2, 3,
Yj | η2 ∼ N(βYj + φYjη2, σ2Yj ), j = 4, 5,
η2 ∼ N(βηη1, σ2η2),
η1 ∼ N(0, σ2η1).
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Figure 2.3. Model Used in Simulation Studies. The SEM consists of two latent variables, an observed
covariate, seven binary or normal manifest variables, and a survival time that regresses on the latent
variable, some manifest variables, and the observed covariates.
We set Z1 and Z2 to independent standard normal and Bernoulli(0.5), respectively, and Λ0(t) = t2.
We considered the class of logarithmic transformations G(x) = r−1 log(1 + rx) with r = 0 or 1,
which correspond to the proportional hazards and proportional odds models, respectively. We
generated the censoring times from Exp(c), where c was chosen to yield approximately 30% censored
observations. We set (Y1, . . . , Y5) to be missing completely at random for 30% of the subjects. We
set the sample size to 400 and set the number of abscissa points to 20 for each Gauss-Hermite
quadrature. We simulated 5,000 datasets for each setting. The results are summarized in Table 2.1.
The estimators of all parameters are virtually unbiased for both the proportional hazards and
proportional odds models. The standard error estimators accurately reflect the true variations,
and the coverage probabilities of the confidence intervals are close to the nominal level. Standard
error estimators for the parameters in the survival model are larger under the proportional odds
model than under the proportional hazards model. As a result, the standard error estimators for
the parameters associated with η2 are larger. The standard error estimators for the remaining
parameters are very similar between the two models.
We also evaluated Mplus (Muthén and Muthén 1998–2015) under the proportional hazards
model, and the results are presented in Table 2.2. The results for the Euclidean parameters are
similar to those presented in Table 2.1. Mplus provides estimator for the baseline hazard function
instead of the cumulative baseline hazard function. Its standard error estimator does not reflect the
true variation, and the coverages of the confidence intervals are far below the nominal level.
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Table 2.1. Simulation Results for the SEM with Two Latent Variables.
Proportional Hazards Model Proportional Odds Model
Dep Ind Param Bias SE SEE CP Param Bias SE SEE CP
T Z1 0.100 0.003 0.075 0.073 0.947 0.100 0.003 0.109 0.107 0.946
Z2 −0.200 −0.005 0.180 0.181 0.953 −0.200 0.002 0.269 0.270 0.950
Y6 0.100 0.000 0.145 0.142 0.947 0.100 0.001 0.212 0.208 0.944
Y7 0.200 −0.001 0.165 0.163 0.949 0.200 0.002 0.238 0.236 0.950
η2 0.500 0.012 0.167 0.166 0.950 0.500 0.014 0.228 0.223 0.948
Λ0(t1) 0.202 0.004 0.050 0.049 0.949 0.212 0.006 0.074 0.072 0.947
Λ0(t2) 0.518 0.010 0.120 0.118 0.949 0.608 0.020 0.206 0.202 0.953
Λ0(t3) 1.103 0.032 0.256 0.249 0.950 1.588 0.076 0.554 0.538 0.950
Y1 Int 0.000 −0.001 0.073 0.073 0.947 0.000 −0.001 0.073 0.073 0.948
Var 1.000 −0.010 0.131 0.128 0.960 1.000 −0.010 0.131 0.128 0.960
Y2 Int 0.000 0.001 0.074 0.073 0.945 0.000 0.001 0.074 0.073 0.945
η1 1.000 0.021 0.210 0.203 0.949 1.000 0.022 0.210 0.204 0.950
Var 1.000 −0.013 0.129 0.128 0.960 1.000 −0.013 0.129 0.128 0.960
Y3 Int 0.000 0.000 0.073 0.073 0.954 0.000 0.000 0.073 0.073 0.954
η1 1.000 0.024 0.211 0.204 0.950 1.000 0.024 0.212 0.204 0.952
Var 1.000 −0.015 0.131 0.128 0.959 1.000 −0.015 0.131 0.128 0.960
Y4 Int 0.000 0.001 0.077 0.076 0.946 0.000 0.001 0.077 0.076 0.946
Var 1.000 −0.025 0.194 0.185 0.956 1.000 −0.029 0.216 0.209 0.951
Y5 Int 0.000 0.001 0.077 0.076 0.950 0.000 0.001 0.077 0.076 0.949
η2 1.000 0.048 0.303 0.279 0.942 1.000 0.060 0.348 0.323 0.945
Var 1.000 −0.030 0.198 0.188 0.957 1.000 −0.036 0.221 0.213 0.954
Y6 Int 0.000 0.004 0.278 0.273 0.953 0.000 0.004 0.277 0.273 0.954
Z1 −0.500 −0.006 0.113 0.113 0.953 −0.500 −0.006 0.113 0.113 0.953
Z2 0.500 0.006 0.301 0.297 0.954 0.500 0.006 0.300 0.297 0.955
η2 0.000 0.003 0.229 0.220 0.964 0.000 0.003 0.231 0.222 0.965
Y7 Int 1.000 0.033 0.347 0.345 0.953 1.000 0.033 0.347 0.345 0.953
Z1 1.000 0.024 0.151 0.148 0.951 1.000 0.024 0.151 0.148 0.951
Z2 0.200 −0.005 0.344 0.342 0.955 0.200 −0.005 0.345 0.342 0.955
Y6 −0.200 −0.009 0.265 0.264 0.952 −0.200 −0.009 0.265 0.264 0.953
η2 0.000 0.003 0.265 0.253 0.960 0.000 0.002 0.268 0.255 0.962
η1 Var 0.500 0.006 0.136 0.134 0.956 0.500 0.006 0.136 0.134 0.955
η2 η1 0.500 0.009 0.153 0.147 0.939 0.500 0.009 0.157 0.151 0.940
Var 0.500 0.009 0.177 0.169 0.960 0.500 0.013 0.196 0.190 0.964
NOTE: Each row corresponds to the regression parameter of the dependent variable “Dep” on the
independent variable “Ind” or some other parameter in the model of “Dep”. “Int” and “Var” stand for
the intercept and error variance, respectively. The parameters Λ0(t1), Λ0(t2), and Λ0(t3) correspond to
the cumulative baseline hazard function values at the 25%, 50%, and 75% quantiles of the survival time.
The true value of a parameter is given under “Param”. “Bias” is the empirical bias; “SE” is the empirical
standard error; “SEE” is the empirical mean of the standard error estimator; and “CP” is the empirical
coverage probability of the 95% confidence interval.
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Table 2.2. Simulation Results for Mplus
Dep Ind Param Bias SE SEE CP
T Z1 0.100 0.003 0.075 0.073 0.947
Z2 −0.200 −0.005 0.180 0.181 0.953
Y6 0.100 0.000 0.145 0.142 0.948
Y7 0.200 0.000 0.165 0.163 0.949
η2 0.500 0.026 0.172 0.169 0.958
λ0(t1) 0.900 0.019 2.353 0.939 0.643
λ0(t2) 1.440 0.016 2.947 1.487 0.689
λ0(t3) 2.100 0.056 4.615 2.203 0.715
Y1 Int 0.000 −0.001 0.073 0.073 0.948
Var 1.000 −0.010 0.131 0.128 0.959
Y2 Int 0.000 0.001 0.074 0.073 0.944
η1 1.000 0.021 0.210 0.203 0.949
Var 1.000 −0.013 0.129 0.128 0.961
Y3 Int 0.000 0.000 0.073 0.073 0.954
η1 1.000 0.023 0.211 0.203 0.950
Var 1.000 −0.015 0.131 0.128 0.960
Y4 Int 0.000 0.001 0.077 0.075 0.945
Var 1.000 0.001 0.189 0.180 0.942
Y5 Int 0.000 0.001 0.077 0.076 0.950
η2 1.000 0.103 0.346 0.306 0.952
Var 1.000 −0.056 0.215 0.200 0.962
Y6 Int 0.000 −0.004 0.278 0.273 0.954
Z1 −0.500 −0.006 0.113 0.113 0.953
Z2 0.500 0.005 0.301 0.297 0.954
η2 0.000 0.003 0.237 0.226 0.961
Y7 Int 1.000 −0.033 0.347 0.345 0.953
Z1 1.000 0.024 0.151 0.148 0.951
Z2 0.200 −0.005 0.344 0.342 0.955
Y6 −0.200 −0.009 0.265 0.264 0.952
η2 0.000 0.003 0.273 0.260 0.960
η1 Var 0.500 0.006 0.136 0.134 0.955
η2 η1 0.500 −0.003 0.155 0.147 0.928
Var 0.500 −0.018 0.169 0.160 0.953
NOTE: Each row corresponds to the regression parameter of the dependent variable “Dep” on
the independent variable “Ind” or some other parameter in the model of “Dep”. “Int” and “Var”
stand for the intercept and error variance, respectively. The parameters λ0(t1), λ0(t2), and
λ0(t3) correspond to the baseline hazard function values at the 25%, 50%, and 75% quantiles of
the survival time. The true value of a parameter is given under “Param”. “Bias” is the empirical
bias; “SE” is the empirical standard error; “SEE” is the empirical mean of the standard error
estimator; and “CP” is the empirical coverage probability of the 95% confidence interval.
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2.6 Real Data Analysis
We analyzed a dataset on patients with serous ovarian cancer from the TCGA project (The
Cancer Genome Atlas Research Network 2011). Genomic variables include DNA copy number, SNP
genotype, DNA methylation level, and levels of expression of mRNA, microRNA, total protein, and
phosphorylated protein. Demographic and clinical variables include age at diagnosis, race, tumor
stage, tumor grade, time to tumor progression, and time to death. There are a total of 586 patients.
The median follow-up time was about 2.5 years, and roughly 30% of the patients were lost to follow-up
before tumor progression or death. The data are available from http://gdac.broadinstitute.org/.
We focused on the integrative analysis of clinical outcomes and expression levels of mRNA,
total protein, and phosphorylated protein. We considered mRNA expression as a latent variable
that can only be observed with error through three microarray platforms, namely Agilent 244K
Whole Genome Expression Array, Affymetrix HT-HG-U133A, and Affymetrix Exon 1.0. We as-
sumed that the effects of a gene on clinical outcomes are mediated through unobserved protein
activity. The latent protein activity is modified by mRNA expression and is manifest through the
observed protein expression measurements, which were obtained from the reverse-phase protein
arrays platform. Figure 2.4 depicts the SEM fit for each gene. We assumed that the observed
variables follow the distributions described in Chapter 2.5, with (Y1, Y2, Y3) being the three mi-
croarray measurements, (Y4, Y5) = (Total protein expression, Phosphorylated protein expression),
(Y6, Y7) = (Tumor stage, Tumor grade), (Z1, Z2) = (Age, Race), and T being progression-free
survival time.
We dichotomized tumor stage into stage II/III versus stage IV and tumor grade into grade 2
versus grade 3/4. Race was dichotomized into white and non-white. We allowed mRNA expression
and protein expression data to be missing for some subjects. We excluded patients with tumor
stage I or grade 1, as those patients may have a disease that is biologically different from that of
patients with tumors of other stages or grades. For each gene, we fit the class of transformation
models with G(x) = r−1 log(1 + rx) over a grid of r = (0, 0.1, . . . , 2). We selected the model with
the smallest AIC or, equivalently, the largest log-likelihood value.
We present the results for the gene ACACA. The sample size is 542. About 30% of the subjects
do not have protein expression data, and over 10% of the subjects miss at least one mRNA expression
measurement. The best-fitting model is obtained at r = 1, which corresponds to the proportional
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odds model. The point estimates and standard error estimates of the parameters associated with
the latent variables are shown in Figure 2.4. The remaining results are shown in Table 2.3. The
latent variables have strong positive association with the measurement platforms. As expected,
latent protein activity and latent mRNA expression are highly correlated. Latent protein activity is
positively associated with progression-free survival time, with a p-value of 0.100. Specifically, higher
latent protein activity is associated with shorter progression-free survival time, which agrees with
the findings of the literature (Menendez and Lupu 2007). The association of ACACA with tumor
stage or tumor grade is weak.
The results for the parameters in the non-survival models are similar between r = 0 and 1. The
parameters in the survival model have different interpretations between r = 0 and 1. With r = 0, a
unit increase in latent protein activity would have a multiplicative effect of exp(0.068) on the hazard
function. With r = 1, a unit increase in the latent protein activity would have a multiplicative effect
of exp(−0.192) on the survival odds. For this dataset, the proportional odds model provides much
stronger evidence for the effect of protein activity on progression-free survival than the proportional
hazards model.
For the Cox proportional hazards model, we also present the results from Mplus in Table 2.3.
The results from NPMLE and Mplus are similar for most parameters. There are considerable
differences between the cumulative baseline hazard function estimates. The standard error estimates
for the cumulative baseline hazard function are not available from Mplus.
Figure 2.4. Results from the SEM Analysis of the Gene ACACA. Analysis results are from 542
patients with ovarian cancer in the TCGA project. The numbers besides an arrow correspond to
the point estimate and standard error estimate (in parentheses) of the regression parameter. The
numbers below the latent variables correspond to the point estimate and standard error estimate (in
parentheses) of the error variance.
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Table 2.3. Analysis Results for the Gene ACACA
NPMLE (r = 1) NPMLE (r = 0) Mplus (r = 0)
Dep Ind Est St Error Est St Error Est St Error
T Z1 0.229 0.086 0.114 0.054 0.114 0.054
Z2 0.038 0.309 0.168 0.192 0.168 0.192
Y6 0.760 0.284 0.436 0.139 0.436 0.139
Y7 0.511 1.118 0.263 0.151 0.263 0.148
η2 0.192 0.116 0.068 0.062 0.068 0.062
Λ0(t1) 0.135 0.143 0.160 0.028 0.160 N/A
Λ0(t2) 0.401 0.415 0.392 0.061 0.394 N/A
Λ0(t3) 1.062 1.061 0.767 0.114 0.771 N/A
Y1 Int 0.004 0.044 0.004 0.044 0.005 0.044
Var 0.286 0.038 0.288 0.038 0.287 0.038
Y2 Int −0.013 0.044 −0.013 0.044 −0.013 0.044
η1 0.687 0.056 0.688 0.056 0.687 0.056
Var 0.658 0.046 0.658 0.046 0.658 0.046
Y3 Int 0.014 0.043 0.014 0.044 0.014 0.043
η1 1.019 0.062 1.022 0.062 1.021 0.062
Var 0.276 0.039 0.274 0.039 0.275 0.039
Y4 Int −0.021 0.048 −0.023 0.049 −0.022 0.048
Var 0.096 0.046 0.097 0.046 0.106 0.045
Y5 Int −0.009 0.048 −0.011 0.049 −0.011 0.048
η2 0.909 0.054 0.910 0.054 0.919 0.054
Var 0.237 0.041 0.236 0.041 0.229 0.041
Y6 Int −1.733 0.128 −1.734 0.128 −1.732 0.128
Z1 −0.290 0.125 −0.290 0.125 −0.289 0.125
Z2 −0.095 0.434 −0.092 0.434 −0.094 0.434
η2 −0.113 0.157 −0.121 0.157 −0.123 0.158
Y7 Int 1.977 0.149 1.977 0.149 1.996 0.151
Z1 0.132 0.135 0.132 0.135 0.133 0.135
Z2 0.001 0.461 0.002 0.461 −0.015 0.462
Y6 −0.055 0.356 −0.054 0.356 −0.072 0.357
η2 0.082 0.162 0.080 0.161 0.081 0.162
η1 Var 0.689 0.068 0.687 0.068 0.687 0.068
η2 η1 0.691 0.062 0.692 0.063 0.690 0.063
Var 0.560 0.063 0.559 0.063 0.551 0.062
NOTE: Each row corresponds to the regression parameter of the dependent variable “Dep” on the independent variable
“Ind” or some other parameter in the model of “Dep”. “Int” and “Var” stand for the intercept and error variance, respectively.
The representation of each variable is given in Chapter 2.6. The parameters Λ0(t1), Λ0(t2), and Λ0(t3) correspond to the
cumulative baseline hazard function values at the 25%, 50%, and 75% quantiles of the progression-free survival, respectively.
The point estimate of and standard error estimate of a parameter are given under “Est” and “St Error”, respectively.
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For comparisons, we also fit a proportional odds model without latent variables for progression-
free survival on the covariates and the two protein expression variables, where the subjects with
missing protein expression data were discarded. The p-value of the Wald test for the joint effect
of protein expression is 0.157. With r = 0, the Wald test p-value is 0.578. Therefore, analyses
based on standard models fail to conclude a strong association between the protein expression and
progression-free survival. The power of the proposed SEM framework stems from the appropriate
handling of missing data, the dimension reduction of the observed covariates, and the flexibility of
the survival model.
2.7 Discussion
In this chapter, we consider semiparametric SEM for potentially right-censored survival time data.
We prove the consistency, asymptotic normality, and semiparametric efficiency of the NPMLE. We
propose new rules for establishing model identifiability and invertibility of the information operator.
We construct an EM algorithm to compute the NPMLE and introduce occasional Newton-Raphson
steps to accelerate the convergence.
One contribution of Theorem 2.1 is that it reduces a semiparametric identifiability problem to a
parametric one; it shows that the inclusion of the semiparametric component does not make the
model less identifiable but, in some sense, makes the model more easily identifiable. With that
being said, the result hinges on correct specification of the model and does not guarantee empirical
identifiability in a finite sample. Therefore, care should be taken when fitting a model that is nearly
non-identifiable. Another main result of ours is given by Lemma 2.1. This lemma is applicable to
a wide range of latent variable models and allows one to deduce the identifiability of a model by
inspecting just part of it.
Invertibility of the information operator has received much less attention in the literature than
model identifiability. In this chapter, we prove a general result for invertibility of the information
operator. It is evident from the proof that the invertibility of the information operator can be
established using techniques similar to those used to establish model identifiability. Specifically,
the key to the proof of the identifiability of the mixture Cox model is that with the presence of a
covariate that is independent of the latent variable, the contributions to the likelihood from the
latent variable and the baseline hazard function can be separated by considering different values of
the covariate. (In a normal mixture model, however, we lack such identifiability results precisely
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because the random effect and error term are combined linearly and their distributions cannot
be distinguished.) As a result, if two sets of parameters give rise to the same marginal survival
function, then they must do so by giving rise to the same random-effect distribution. Based on the
proportional hazards structure, we prove a parallel result for the invertibility of the information
operator: the existence of a submodel with zero score implies that the random-effect distribution
has zero score along that submodel as well. Therefore, to ensure the invertibility of the information
operator of the mixture Cox model, one only has to ensure that the information matrix of the
random-effect distribution is invertible.
Our work can be extended in several directions. First, one may be interested in expanding the
model by inclusion of more latent and observed variables. As the number of variables increases,
the number of parameters to be estimated increases as well. Then, it may be desirable to perform
variable selection. Because a single variable may be associated with multiple parameters, one
may prefer not to treat parameters as the basic unit of selection, as in traditional lasso methods
(Tibshirani 1996). Instead, methods like group lasso (Yuan and Lin 2006) that penalize parameters
associated with a variable as a group may be considered.
In our model, the distribution of the manifest variable Y is fully parametric. One can allow a
nonparametric transformation on Y . A major challenge arises in extending the asymptotic results
to unbounded nonparametric transformation, as the estimator of the transformation function can
be unbounded (Zeng and Lin 2010).
Finally, it would be of interest to consider interval-censored data. Interval censoring results in a
different likelihood function, which makes the computation of the NPMLE and the derivation of its
asymptotic properties challenging, even for univariate survival time data. The asymptotic theory
for interval-censored data is only available in a few simple cases; see Huang and Wellner (1997) for
a review.
2.8 Technical Details
We present the following conditions, which are clearly implied by conditions (C3)-(C5):
(C3’) For k = 1, . . . ,K1, ϑk is a non-zero vector.
(C4’) Consider two sets of parameters (αk,βk,ψ,ν) and (α̃k, β̃k, ψ̃, ν̃) for k = 1, . . . ,K1, and let
η̃1 = (η̃11, . . . , η̃1K1), where η̃1k = Y T(αk− α̃k) +ZT(βk− β̃k) + η1k. Let fY,η1 be the density
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of (Y ,η1) given Z. Then, fY,η1(Y ,η1 | Z;ψ,ν) = fY,η1(Y , η̃1 | Z; ψ̃, ν̃) for all Z, Y , and η1
implies that αk = α̃k, βk = β̃k, ψ = ψ̃, and ν = ν̃.
(C5’) For k = K1 + 1, . . . ,K, let (Y (k),η(k)1 ,η
(k)
2 ) be the components of (Y ,η1,η2) that appear




2 ) be the remaining components. If η
(k)
2 is
non-empty, then (Y −(k),η−(k)1 ) is non-empty, and η
(k)
2 is complete sufficient in {Fη(k)2 |Y,η1
(· |
Z,Y ,η1) : Z = z0,Y (k) = y0,η
(k)
1 = η10} for any fixed z0, y0, and η10, where Fη(k)2 |Y,η1
is
the distribution function of η(k)2 given (Z,Y ,η1) with (Y −(k),η
−(k)
1 ) treated as a parameter
vector.
We prove Theorem 2.1 under the generalized conditions (C1), (C2), and (C3’)-(C5’). The proof
makes use of two lemmas given at the end of this section. We first provide an overview of the proof.
For any two sets of parameters (ϑk,αk,βk,φk,Λk,ψ,ν) and (ϑ̃k, α̃k, β̃k, φ̃k, Λ̃k, ψ̃, ν̃), assume that
the likelihood values at the two sets of parameters are identical almost surely. By definition, the
model is identifiable if the equality of the likelihood values implies the equality of the two sets of
parameters. We derive the equality of the two sets of parameters in the following steps:
1. By conditions (C1), (C2), and (C3’) and the identifiability of the mixture Cox model (Kortram
et al. 1995), ϑk = ϑ̃k and Λk = Λ̃k for k = 1, . . . ,K1.
2. With some algebraic manipulation, the likelihood function can be expressed in the form of
the Laplace transform of the distribution of a function of (Y ,η1). The uniqueness of the
Laplace transform, together with condition (C4’), implies that (αk,βk,ψ,ν) = (α̃k, β̃k, ψ̃, ν̃)
for k = 1, . . . ,K1.
3. By the uniqueness of the Laplace transform and the complete sufficiency of η2 imposed by
condition (C5’), the equality of the likelihood functions of (TK1+1, . . . , TK ,Y ) implies the
equality of the likelihood functions of (TK1+1, . . . , TK ,Y ,η). By the identifiability of the Cox
model, we conclude that (ϑk,αk,βk,φk) = (ϑ̃k, α̃k, β̃k, φ̃k) for k = K1 + 1, . . . ,K.
Proof of Theorem 2.1. The likelihood is given in (2.4). Here, we consider a single observation and
drop the subscript i. Using the arguments in Section 10.1 of Zeng and Lin (2010), we can set each
survival time to be right censored at any time point within [0, τ ] when establishing identifiability.
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Consider two sets of parameters (ϑk,αk,βk,φk,Λk,ψ,ν) and (ϑ̃k, α̃k, β̃k, φ̃k, Λ̃k, ψ̃, ν̃) such that































Y ,η | Z; ψ̃, ν̃
)
dη
for all t1, . . . , tK ∈ [0, τ ], W , Z, and Y , where fY,η is the density of (Y ,η) given Z. If mk is a
point mass at one, then sk is fixed at one, gk = 1, and the integration with respect to mk(sk) can
be omitted. For simplicity of description, assume that mk is the Lebesgue measure. Note that
ˆ






e−tsgk (s) ds = − lim
t→0+
d
dt exp {−Gk (t)} = G
′
k (0) <∞.
Thus, a transformation model can be written as a random-effect proportional hazards model with
known distributions (g1, . . . , gK) for random effects (s1, . . . , sK) with finite means.
First, we show that the baseline hazard functions of the first K1 survival times are identifiable.
For each k = 1, . . . ,K1, set tl → 0 for l 6= k on both sides of (2.5). On each side of the resulting
equation, integration with respect to Y results in the likelihood of a mixture Cox model with
ske
Y Tαk+η1k or skeY
Tα̃k+η1k as a latent variable. Let E(· | Z) and Ẽ(· | Z) be the expectations
under fY,η(· | Z;ψ,ν) and fY,η(· | Z; ψ̃, ν̃), respectively. Theorem 3 of Kortram et al. (1995)
implies that E(skeY
Tαk+η1k | Z = 0)Λk = Ẽ(skeY
Tα̃k+η1k | Z = 0)Λ̃k on [0, τ ], ϑk = ϑ̃k, and the
distribution of E(skeY
Tαk+η1k | Z = 0)−1skeY
Tαk+η1k under fY,η(· | Z;ψ,ν) is equal to that of
Ẽ(skeY
Tα̃k+η1k | Z = 0)−1skeY
Tα̃k+η1k under fY,η(· | Z; ψ̃, ν̃). Because E(Y Tαk + η1k | Z = 0) =
Ẽ(Y Tα̃k + η1k | Z = 0) = 0 by condition (C2), we see that Λk = Λ̃k on [0, τ ].
Second, we show that the likelihood function takes the form of a Laplace transform and use the
uniqueness of the Laplace transform to prove the identifiability of (αk,βk,ψ,ν) (k = 1, . . . ,K1).


























Y ,η | Z; ψ̃, ν̃
)
dη. (2.6)
Let U = (U1, . . . , UK1), Uk = skeη1k , and fU |Y be the density function of U given Z and Y . By
the uniqueness of the Laplace transform, for any continuous functions f and f̃ , any open set S, and
any positive real numbers c and c̃,
ˆ ∞
0
e−cstf (t) dt =
ˆ ∞
0
e−c̃stf̃ (t) dt ∀s ∈ S
implies that f(t) = (c/c̃)f̃(ct/c̃) for all t > 0. Therefore, the equality of (2.6) for all t1, . . . , tK1 , Z,
and Y implies that
fU |Y
(







Ũ | Z,Y ; ψ̃, ν̃
)
(2.7)
for all U , Z, and Y , where Ũ = (Ũ1, . . . , ŨK1), and Ũk = eZ
T(βk−β̃k)+Y T(αk−α̃k)Uk. Let fη1|Y be
the density of η1 given Z and Y . By the definition of U ,




fη1|Y (logU1 − log s1, . . . , logUK1 − log sK1 | Z,Y ;ψ,ν)
K1∏
k=1




fη1|Y (logU1 − v1, . . . , logUK1 − vK1 | Z,Y ;ψ,ν)
K1∏
k=1
U−1k ḡk (vk) e
vk d (v1, . . . , vK1) ,











log Ũ1 − v1, . . . , log ŨK1 − vK1 | Z,Y ; ψ̃, ν̃
)} K1∏
k=1
ḡk (vk) evk d (v1, . . . , vK1) = 0.











for any s such that the integrals are defined, where (f ∗g)(t) ≡
´∞
−∞ f(t−s)g(s) ds is the convolution






e−stg (t) dt = 0,
which, if g is positive, implies that f(·) = 0 by the uniqueness of the bilateral Laplace trans-
form (Chareka 2007). Because ḡk(·)e(·) is positive, (2.8) implies that fη1|Y (η1 | Z,Y ;ψ,ν) =
fη1|Y (η̃1 | Z,Y ; ψ̃, ν̃), where η̃1 is defined in condition (C4’). By condition (C4’), (αk,βk,ψ,ν) =
(α̃k, β̃k, ψ̃, ν̃) for k = 1, . . . ,K1.
It remains to identify the parameters associated with (TK1+1, . . . , TK). By the uniqueness of the








Tφk gk (sk) dsk
}









Tφ̃k gk (sk) dsk
}
fY,η (Y ,η | Z;ψ,ν) dη2
for all tK1+1, . . . , tK , W , Z, Y , and η1, i.e., η1 can be treated as observed for identifying the
remaining parameters. Under condition (C5’), we can use the arguments in the proof of Lemma 2.1
to show that the integrands in the above equality are equal at each value of η2. We conclude that
(ϑk,αk,βk,φk,Λk) = (ϑ̃k, α̃k, β̃k, φ̃k, Λ̃k) for k = K1 + 1, . . . ,K.
We provide an overview for the proof of Theorem 2.2. The consistency of the NPMLE is proved
in the following steps:
1. By conditions (D2)-(D4), the NPMLE exists, i.e., Λ̂k(τ) <∞.
2. By conditions (D3) and (D4), Λ̂k(τ) is uniformly bounded. Helly’s selection theorem then
implies that every subsequence of Λ̂k has a further converging subsequence.
3. By the Glivenko-Cantelli properties of the log-likelihood and related functions given by Lemma
2.3, the identifiability of the model, and the non-negativity of the Kullback-Leibler divergence,
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we conclude the consistency of the NPMLE.
The asymptotic normality of the NPMLE follows mainly from the arguments of van der Vaart (1998,
pp. 419–424). Donsker properties of the score and related functions are given by Lemma 2.4, and
the invertibility of the information operator is given by Lemma 2.2.
Proof of Theorem 2.2. We use Z to denote both W and Z with βk (k = 1, . . . ,K) being the












































Ψ̇θ(Oi;θ,A) be the derivative of Ψ(Oi;θ,A) with respect to θ, and Ψ̇k(Oi;θ,A)[Hk] be the derivative
of Ψ(Oi;θ,A) along the path (Λk + εHk).











































where F(Oi;θ) is a random variable with |E{logF(Oi;θ)}| < ∞ for any θ. By condition (D2),
P (T̃ki = τ) is positive. Therefore, if Λk (τ) =∞, then the right-hand side of (2.9) is zero for large
n. We conclude that Λ̂k (τ) <∞, such that the NPMLE exists.











































Let Ñ = n−1
∑n
i=1(∆1iI(T̃1i ≤ ·), . . . ,∆KiI(T̃Ki ≤ ·)). Clearly,
1
n
















































Note that (κ3k − κ2k − 1) is positive by condition (D4). Using the partitioning argument similar
to those of Murphy (1994) and Parner (1998), we can show that the right-hand side of the above
inequality tends to −∞ if lim supn Λ̂k (τ) = ∞. By definition of (θ̂, Â), the left-hand side of the
inequality is bounded below by an Op(1) term. Therefore, Λ̂k (τ) is uniformly bounded.
Given the boundedness of Λ̂k (τ), Helly’s selection theorem implies that, for any subsequence of
n, we can always choose a further subsequence such that Λ̂k converges pointwise to some monotone
function Λ∗k and θ̂ converges to θ
∗. The desired consistency result follows if we can show that
Λ∗k = Λ0k and θ
∗ = θ0 almost surely. With an abuse of notation, let {n}1,2,... be the subsequence.
Define





































uniformly on [0, τ ]. Because the score function along the path Λk = Λ0k + εI (· ≥ s) with other






















∣∣∣n−1∑nj=1 Ψ̇k(Oj ;θ0,A0)[I (s ≤ ·) ]/Ψ(Oj ;θ0,A0)∣∣∣∣∣∣n−1∑nj=1 Ψ̇k(Oj ; θ̂, Â)[I (s ≤ ·) ]/Ψ(Oj ; θ̂, Â)∣∣∣ dΛ̃k (s) .
We have shown that the numerator of the integrand in the above equation converges uniformly.
Similarly, we can show that the denominator of the integrand in the above equation converges
uniformly to |E{Ψ̇k(Oi;θ∗,A∗)
[
I (s ≤ ·)
]
/Ψ(Oi;θ∗,A∗)}| and that the limit is bounded away from
0. Because Λ̃k converges uniformly to Λ0k, which is differentiable with respect to t, Λ∗k is also
differentiable with respect to t. It follows that dΛ̂k/dΛ̃k converges uniformly to λ∗k/λ0k on [0, τ ],



















log Ψ(Oi; θ̂, Â)
Ψ(Oi;θ0, Ã)
≥ 0.
By the Glivenko-Cantelli properties of the class of functions of log Ψ(Oi;θ,A) given by Lemma 2.4













The left-hand side of the above inequality is the negative Kullback-Leibler distance of the density
indexed by (θ∗,A∗). From the identifiability of the model implied by Theorem 2.1, we conclude
that θ∗ = θ0 and Λ∗k = Λk0. The desired consistency result follows.
To prove the asymptotic normality of the NPMLE, we adopt the arguments of van der Vaart
(1998, pp. 419–424). Let Pn be the empirical measure determined by n i.i.d. observations, and let
P be the true probability measure. Let ˙̀θ(θ,A) be the derivative of logLn(θ,A) with respect to θ,
and let ˙̀k(θ,A)[Hk] be the derivative of logLn(θ,A) along the path (Λk + εHk). For any v ∈ Rd
and W = (h1, . . . , hK) with hk ∈ BV [0, τ ], where BV [0, τ ] is the space of functions of bounded
variation on [0, τ ], we have
Pn
(




























































From the Donsker properties of the classes of functions of ˙̀θ and ˙̀k implied by Lemma 2.4 and the














+ op (1) .
This term converges to a Gaussian process in l∞(V × QK). By the Taylor series expansion, the




















where B ≡ (B1, B21, . . . , B2K) is the information operator and is linear in Rd × BV [0, τ ]K . By
Lemma 2.2, B is invertible. The rest of the proof then follows the arguments of van der Vaart (1998,
pp. 419–424). Finally, because vTθ̂ is an asymptotically linear estimator of vTθ0 with the influence
function lying in the space spanned by the score functions, θ̂ is an efficient estimator for θ0.
The following four lemmas are used to prove Theorem 2.1 and Theorem 2.2.
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Lemma 2.1. Let Model A be
X | (η1,η2)
d= X | η1 ∼ FX|η1 (· | η1) ,
Y | (η1,η2) ∼ FY |η (· | η1,η2) ,
η2 | η1 ∼ Fη2|η1 (· | η1) ,
η1 ∼ Fη1 ,
where (X,Y ) are observed, and (η1,η2) are latent. Model A is depicted in Figure 2.5. Let
fX|η1 = F ′X|η1, fY |η = F
′
Y |η, fη2|η1 = F
′
η2|η1, and fη1 = F
′
η1. Assume that: (a) for any density
functions f̃Y |η and f̃η2|η1,
ˆ
fY |η (Y | η1,η2) fη2|η1 (η2 | η1) dη2 =
ˆ
f̃Y |η (Y | η1,η2) f̃η2|η1 (η2 | η1) dη2 ∀Y ,η1
implies that (fY |η, fη2|η1) = (f̃Y |η, f̃η2|η1), i.e., the model for Y is identifiable if η1 is observed; (b)
FX|η1 and Fη1 are identifiable based on (X,Y ); and (c) η1 is a complete sufficient statistic in
{Fη1|X(· | X) : X ∈ X}, where Fη1|X is the conditional distribution function of η1 given X, and
X is the range of X. Then, Model A is identifiable. A sufficient condition for η1 to be complete
sufficient is that the density of X is of the form
fX|η1 (X | η1) ∝
q∏
j=1
exp {Xjsj (η1)− aj (η1)} bj (Xj) ,
where X = (X1, . . . , Xq), η1 7→ (s1(η1), . . . , sq(η1)) is one-to-one, and bj is non-zero on some open
set.
Figure 2.5. SEM Considered in Lemma 2.1. The SEM consists of two sets of latent variables and
two sets of observed variables that may all be multivariate. The observed variable X depends only
on the latent variable η1, but the observed variable Y depends on both sets of latent variables.
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Lemma 2.2. Under conditions (C1), (C2), (C3’), (C5’), and (D5), the model given by (2.1)-(2.3)
has an invertible information operator.
Lemma 2.3. Consider functions h and g in the space l∞(Rr × Rq). Assume that for any Y ∈ Rr
and b ∈ Rq, there exist Mj > 0, cj > 0, and N j ∈ Rr (j = 1, . . . , q) such that
q∏
j=1
exp(−Mj |bj |+NTj Y bj − cjb2j ) ≤ h (Y , b) ≤
q∏
j=1
exp(Mj |bj |+NTj Y bj − cjb2j ),





− eA1+BTY +1Tq b
)
h (Y , b) g (Y , b) db´
exp
(
− eA2+BTY +1Tq b
)
h (Y , b) db
(2.11)
and ´
h (Y , b) g (Y , b) db´
h (Y , b) db (2.12)
are bounded by eO(1+|Y |) for any A1 ∈ R, A2 ∈ R, and B ∈ Rr.
Lemma 2.4. The following classes are Donsker:
C1 =
{














: ‖Λm‖V [0,τ ] ≤ c,m = 1, . . . ,K,θ ∈ Θ, ‖H‖V [0,τ ] ≤ c
}
for k = 1, . . . ,K and any fixed c > 0, where Ψ, Ψ̇θ, and Ψ̇k are defined in the proof of Theorem 2.2.
Proof of Lemma 2.1. Assume that there exist two sets of density functions (fY |η, fη2|η1) and
(f̃Y |η, f̃η2|η1), such that the marginal densities are identical for all X and Y . That is,
ˆ
fX|η1 (X | η1) fY |η (Y | η) fη2|η1 (η2 | η1) fη1 (η1) dη
=
ˆ
fX|η1 (X | η1) f̃Y |η (Y | η) f̃η2|η1 (η2 | η1) fη1 (η1) dη,
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where η = (η1,η2). Thus, with fη1|X = F ′η1|X ,
ˆ {ˆ
fY |η (Y | η) fη2|η1 (η2 | η1)− f̃Y |η (Y | η) f̃η2|η1 (η2 | η1) dη2
}
fη1|X (η1 |X) dη1 = 0
for all X and Y . Because η1 is complete sufficient in Fη1|X ,
ˆ
fY |η (Y | η1,η2) fη2|η1 (η2 | η1) dη2 =
ˆ
f̃Y |η (Y | η1,η2) f̃η2|η1 (η2 | η1) dη2 ∀Y ,η1.
By assumption, (fY |η, fη2|η1) = (f̃Y |η, f̃η2|η1). Therefore, Model A is identifiable.
To show the complete sufficiency of η1 under the sufficient condition, note that the density of
η1 |X is of the form





 f∗ (η1) ,
where f∗ is a function of η1 that does not involve X. Thus, as a property of the exponential family,
s(η1) ≡ (s1(η1), . . . , sq(η1)) is complete sufficient under the model with parameter X ∈ X . Because
s is a one-to-one function, η1 is complete sufficient.
Proof of Lemma 2.2. With an abuse of notation, we use ν to denote all parameters in FY and Fη and
drop the parameter vector in the arguments of the density functions. We consider the one-dimensional
submodel along (hϑ,hβ,hα,hφ,hν , h1 (·) , . . . , hK (·)) for parameters (ϑ,β,α,φ,ν,Λ1, . . . ,ΛK),
where ϑ = (ϑ1, . . . ,ϑK), and hϑ ≡ (hϑ1, . . . ,hϑK) is partitioned accordingly. We define β,
α, φ, hβ, hα, and hφ in the same way. A one-dimensional submodel along the direction
h ≡ (hθ, h1(·), . . . , hK(·)) ∈ Rd × BV [0, τ ]K indexed by ε is constructed by setting θ = θ0 + εhθ
for the vector of all Euclidean parameters θ and Λk(·) =
´ (·)
0 {1 + εhk(s)}dΛk(s) for k = 1, . . . ,K.
By the arguments in the proof of Theorem 2.1, we can consider the likelihood with the survival
times being right censored at any values within [0, τ ]. For an observation with the K survival times
right censored at (t1, . . . , tK), the likelihood is given by the left-hand side of (2.5). For simplicity of
description, assume that mk is the Lebesgue measure. If the score is zero almost surely, then
ˆ ˆ
exp {−H (t)} g (s) ∂
∂ν











WThϑk +ZThβk + Y Thαk + ηThφk + hk (ω) dΛk (ω) ds dη = 0 (2.13)
for all t1, . . . , tK , W , Z, and Y , where H (t) =
∑K
k=1 Λk(tk)skeW
Tϑk+ZTβk+Y Tαk+ηTφk , s =
(s1, . . . , sK)T, and g(s) =
∏K
k=1 gk(sk). For k = 1, . . . ,K1, we differentiate (2.13) with respect to tk








η1kg (s) fY (Y | Z,η) fη (η | Z) dη ds
{
WThϑk +ZThβk + Y Thαk + hk (0)
}
= 0.
By linear independence of W , hϑk = 0.
Consider the first survival time T1. Because eW
Tϑ1 takes at least two distinct values by conditions
(C1) and (C3), we assume, without loss of generality, that it takes 1 and c with c < 1. Let U1 = s1eη11 ,
and let fY,U1 be the density of (Y , U1) given Z. Setting t2, . . . , tK → 0 and eW

























ZThβ1 + Y Thα1
)
U1e
ZTβ1+Y Tα1fY,U1 (Y , U1 | Z)
}
dU1
≡ a {Λ1 (t1)} . (2.14)
Likewise, setting t2, . . . , tK → 0 and eW
Tϑ1 = c in (2.13), we have ca{Λ1(t1)} = a
{
cΛ1(t1)}. Thus,
for all v ∈ [0,Λ1(τ)], a′(cnv) = a′(v) for any integer n. It follows that a′(v) = a′(0), such that a is a





















ZThβ1 + Y Thα1
)
U1e















κ1 +ZThβ1 + Y Thα1
) ∂
∂U1
{U1fY,U1 (Y , U1 | Z)}
]
dU1 = 0
for all v ∈ [0,Λ1(τ)], Z, and Y . By the uniqueness of the Laplace transform, the term in the square










κ1 +ZThβ1 + Y Thα1
) ∂
∂U1
fY,η̄1 (Y , logU1 − log s | Z)
}
g1 (s) ds = 0.
By the arguments for convolution in the proof of Theorem 2.1,
∂
∂ν
fY,η̄1 (Y , η11 | Z)
T hν −
(
κ1 +ZThβ1 + Y Thα1
) ∂
∂η11
fY,η̄1 (Y , η11 | Z) = 0
for all η11. Multiplying both sides of the above equation by η11 and then integrating with respect to
(Y , η11) at Z = 0, we obtain
∂
∂ν
E (η11 | Z = 0)T hν + E
(
Y Thα1 | Z = 0
)
+ κ1 = 0.
It then follows from condition (C2) that κ1 = 0. Thus, h1(·) = 0.
Assume that hk−1(·) has been shown to be a zero function for some k = 2, . . . ,K1. Let



























ZThβl + Y Thαl
)
sle
WTϑl+ZTβl+Y Tαl+η1lfY,η̄k (Y , η̄k | Z)
−skeW
Tϑk+ZTβk+Y Tαk+η1kfY,η̄k (Y , η̄k | Z)
ˆ tk
0
ZThβk + Y Thαk + hk (ω) dΛk (ω)
]
dη̄k ds
equals zero for all t1, . . . , tk,W , Z, and Y . By the uniqueness of the Laplace transform, we conclude
that hk(ω) = κkω for some κk ∈ R and
∂
∂ν
fY,η̄k (Y , η̄k | Z)
T hν + κk
∂
∂η1k





ZThβl + Y Thαl
) ∂
∂η1l
fY,η̄k (Y , η̄k | Z) = 0.
Multiplying both sides of the above equation by (η11 × · · · × η1k) and then integrating with respect
to (Y , η̄k) at Z = 0, we have κk = 0 and hk(·) = 0. By induction,
∂
∂ν





ZThβk + Y Thαk
) ∂
∂η1k
fY,η1 (Y ,η1 | Z) = 0 ∀Z,Y ,η1.
It then follows from condition (D5) that hν = 0, hβk = 0, and hαk = 0 for k = 1, . . . ,K1.
Consider the left-hand side of (2.13). The first term and the first K1 terms in the summation of
the second term have been shown to be zero. Thus, the left-hand side of (2.13) can be viewed as






















WThϑk +ZThβk + Y Thαk + ηThφk + hk (ω) dΛk (ω)
}
dη2 = 0





















WThϑk +ZThβk + Y Thαk + ηThφk + hk (ω) dΛk (ω)
}
dη(k)2 dsk = 0
for all tk, η1,W , Z, and Y , where fη(k)2 |Y,η1
is the density of η(k)2 given (Z,Y ,η1). By condition (C5),
η
(k)
2 is complete sufficient in fη(k)2 |Y,η1
with (Y −(k),η−(k)) as parameters. Because Y Tαk + ηTφk




WThϑk +ZThβk + Y Thαk + ηThφk + hk (ω) dΛk (ω) = 0 ∀tk ∈ [0, τ ] ,η,W ,Z,Y .
Thus, hϑk = 0, hβk = 0, hαk = 0, and hφk = 0. Therefore, hk(·) = 0.
We have shown that the information operator is one-to-one. Using the arguments of Zeng and
Lin (2010), we can show that it is also a Fredholm operator. Therefore, the invertibility of the
information operator follows.
Proof of Lemma 2.3. Without loss of generality, assume that Y is a scalar. Clearly,
h (Y, b) g (Y, b) ≤
q∏
j=1
exp{K (1 + |Y |) + (Mj +K) |bj |+NjY bj − cjb2j}.







4c + (M +K)
∣∣∣∣NY2c
∣∣∣∣+ N2Y 24c .
Similarly,
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where c−1/2 = (c−1/21 , . . . , c
−1/2




(−1)k(Mj+K)/2cj+(B+Nj/2cj)Y for k = 1, 2.
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Therefore, the fraction in (2.15) is finite if
∑
j(B +Nj/2cj)Y → −∞. If
∑
j(B +Nj/2cj)Y →∞,


























































































logw2 − log logw2 + 2 log
∣∣∣c−1/2∣∣∣+ o (1)} ].
The Y 2 terms in the exponent cancel out; therefore, (2.11) is bounded by eO(1+|Y |).
Proof of Lemma 2.4. We use Z to denote both W and Z with βk (k = 1, . . . ,K) as the corre-


















































Ωki (η) fY (Y i | Zi,η;ψ) fη (η | Zi;ν) dη
}−1
,











i αk+ηTφkG′k {qki (θ,A)}
]∆ki exp [−Gk {qki (θ,A)}] .















eO(1+|Y i|+|η|). Therefore, the first integral term on the right-hand side of (2.16) is bounded above
by ˆ
Ωki (η) eO(1+|Y i|+|η|)fY
(







Condition (D3) states that either Gk(x)/ log x → Mk or Gk(x)/xρk → Mk as x → ∞. If
Gk(x)/xρk → Mk, then we can find M1k > 0, M2k > 0, C1k ∈ R, and C2k ∈ R such that
M2kx












for some A1, A2, B, and C. After transforming η to b using the transformation S specified in
condition (D3), we see that (2.16) is bounded by a term of the form (2.11) and is in turn bounded




/ log x→Mk, then (2.16) is bounded by a term of
the form (2.12), which is also bounded by eO(1+|Y i|). Similarly, the derivatives of log Ψ(Oi;θ,A)
with respect to other parameters are bounded by eO(1+|Y i|).
By Theorem 2.7.5 of van der Vaart and Wellner (1996), the bracket covering number for
any bounded set in BV [0, τ ] is of the order exp {O (1/ε)}. Therefore, we can construct Nε ≡
1/εd × exp{O(K/ε)} brackets for Θ×BV [0, τ ]K , denoted by {(θLj ,ALj ), (θUj ,AUj )} (j = 1, . . . , Nε),
where |θUj − θLj | < ε, and
ˆ τ
0
∣∣∣ΛUkj(t)− ΛLkj(t)∣∣∣2 E{eO(1+|Y i|) dI(T̃ki ≤ t)} < ε2.
By the mean-value theorem, for any (θ1,A1) and (θ2,A2),
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j = 1, . . . , Nε, constitute a bracket cover for C1, where the L2(P)-distance within each bracket pair
is of the order ε. Therefore, the bracket entropy of C1 is finite, such that C1 is Donsker. Similarly,
the classes C2 and C3k can also be shown to be Donsker.
49
CHAPTER 3
ROBUST SCORE TESTS WITH MISSING DATA IN MULTI-PLATFORM
GENOMICS STUDIES
3.1 Introduction
Recent technological advances have made it possible to measure multiple genomics platforms
on the same set of subjects. However, constraints regarding cost and other factors prohibit
measurement of all platforms on all study subjects. For example, in The Cancer Genome Atlas
(TCGA) (https://cancergenome.nih.gov/), over 10,000 subjects with 33 cancer types were measured
on multiple genomics platforms, including somatic mutation, copy number variation, and expressions
of microRNA, mRNA, and protein, but for a substantial number of subjects, data on RNA sequencing
and protein expressions were not generated. As another example, in the National Heart, Lung,
and Blood Institute’s Exome Sequencing Project (https://esp.gs.washington.edu/), only 7,000
subjects with specific diseases or conditions were selected for whole-exome sequencing from the
tens of thousands of total subjects with genotyping array data (Lin et al. 2013). Finally, in the
Trans-Omics for Precision Medicine (TOPMed) program (https://www.nhlbi.nih.gov/research/
resources/nhlbi-precision-medicine-initiative/topmed) and the Genome Sequencing Program (GSP)
(http:// gsp-hg.org), whole-genome sequencing data will be available on hundreds of thousands of
subjects, but other genomics platforms, such as RNA sequencing, methylation, and metabolites,
will be available for only a few thousand subjects through ancillary studies of specific diseases.
It is desirable to infer missing data on one genomics platform using available data from other
platforms. Indeed, this has become a routine practice with genotype data, where linkage disequilib-
rium allows one to impute, with great accuracy, sequencing data from genotyping array data (Li
et al. 2010; Auer et al. 2012). A far greater challenge is to infer missing values for a quantitative
measurement, such as the expression of RNA or protein, from other quantitative measurements or
from SNP genotype data due to the complex and noisy relationships among those variables (Kim
et al. 2005; Torres-García et al. 2009).
Several authors have considered missing data in the context of association testing, which is of
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primary interest in genomics studies. Specifically, Hu et al. (2015) studied the score test based on
imputed genotype data and proposed a variance estimator that properly accounts for the differential
quality between observed and imputed genotypes. The method requires that the imputation is
unbiased and the genotype is independent of the other variables in the phenotype model. Derkach
et al. (2015) and Lawless (2016) proposed to model the variable with missing values under outcome-
dependent sampling and studied the score test based on the full likelihood. Derkach et al. (2015)
assumed a nonparametric model for the variable with missing values and restricted covariates to only
a few possible values. Lawless (2016) assumed a full parametric missing-data model. All existing
methods require unbiased imputation or correct modeling of the variable with missing values. This
is difficult to achieve, especially when the number of covariates in the missing-data model is not
small.
In this chapter, we investigate the validity of the score test with imputed data when the
missing-data mechanism may depend on the phenotype and covariates. In particular, we show
that a condition weaker than correct specification of the missing-data model is sufficient for the
score statistic to be unbiased. Based on this finding, we propose a robust score test which, unlike
existing methods, preserves the type I error under general missing-data mechanisms even when the
imputation model is misspecified. The proposed score statistic is based on a semiparametric model
for the variable with missing values, where covariates enter the model linearly and also through
a one-dimensional nonparametric function. As a result, the test is feasible with a large number
of covariates in the missing-data model. The proposed methodology is applicable to all common
phenotype models and encompasses continuous, binary, and right-censored phenotypes.
In Chapter 3.2, we formulate the problem, investigate the validity of the standard score test
under various missing-data mechanisms, and develop the robust score test. In Chapter 3.3, we
report results from simulation studies that compare the proposed and existing methods. In Chapter
3.4, we provide an application to a dataset from TCGA. We make concluding remarks in Chapter
3.5 and relegate technical details to the Chapter 3.6.
3.2 Methods
Consider a genomics study that involves phenotype Y , genomic variable of interest S, and vector
of covariates X. For example, Y may represent disease status, S may represent the RNA expression
of a gene, and X may include genomic variables associated with S, such as the mutation status
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and copy number of the gene, or non-genomic variables, such as tumor stage, age, and ancestry.
Let f(·;βS + γTX, ζ) denote the density function of Y conditional on (S,X), where β and γ are
regression parameters, and ζ is a set of nuisance parameters that may be infinite-dimensional; this
is referred to as the phenotype model. In particular, ζ is the dispersion parameter in the generalized
linear model and the baseline hazard function in the proportional hazards model. We allow S to
be missing and let R indicate, by values of 1 versus 0, whether S is observed or not, respectively.
Let Z be a set of predictors for S that includes X, as well as variables that are not present in
the phenotype model. The extra variables in Z are exogenous variables that affect Y indirectly
through S and X, such that Z is independent of Y conditional on X under β = 0. The observed
data consist of (Yi, SiRi, Ri,Zi) for i = 1, . . . , n.
We are interested in testing the null hypothesis H0 : β = 0. Among the three common tests,
namely the Wald’s test, the likelihood ratio test, and the score test, the first two require fitting the
model under the alternative hypothesis, which involves estimation of the conditional distribution
of S given X in the presence of missing values for S. If the model for S is misspecified (which
is inevitable when the dimension of X is moderately high), then the estimators of the nuisance
parameters may be inconsistent, such that the resulting tests are invalid. By contrast, the score test
only requires fitting the model under the null hypothesis. As a result, the score test requires fewer
assumptions on the missing-data model than the other two tests in order to yield correct type I
error. Therefore, we focus on the score test in the rest of this chapter.
The score statistic for β at β = 0 takes the form of A(Y,X;ψ)S, where A(Y,X;ψ) =
∂ log f(Y ; t + γTX, ζ)/∂t |t=0, and ψ = (γ, ζ). Note that E{A(Y,X;ψ0) | X} = 0, where
ψ0 ≡ (γ0, ζ0) is the true value of ψ. This formulation includes many common models as special
cases. For the linear model, A(Y,X;ψ) = σ−2(Y − γTX), where σ2 is the error variance. For the
logistic model, A(Y,X;ψ) = Y − eγTX/(1 + eγTX). For the proportional hazards model with right
censoring, A(Y,X;ψ) = ∆ − Λ(T̃ )eγTX , where Y = (T̃ ,∆), T̃ = min(T,C), ∆ = I(T ≤ C), T is
the survival time of interest, C is the censoring time, I(·) is the indicator function, and Λ is the
cumulative baseline hazard function.
We consider the score statistic based on the imputed S. We specify an imputation model of S
that depends on Z and a set of parameters ξ. Let S̃(Zi; ξ̂) be the imputed value of Si, where ξ̂ is
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an estimator of ξ. The (normalized) imputation “score” statistic is




A(Yi,Xi; ψ̂){RiSi + (1−Ri)S̃(Zi; ξ̂)},
where ψ̂ ≡ (γ̂, ζ̂) is an estimator of ψ under H0. At β = 0, the score statistic based on the full
likelihood with a regression model of S on Z takes the form of U impβ . However, the proposed
imputation score statistic is more general in that S̃ needs not be the posterior mean of S (given the
observed data) evaluated at the maximum likelihood estimator of ξ. Let ξ∗ be the limit of ξ̂. The
following proposition provides a general sufficient condition for the unbiasedness of the imputation
score statistic under H0.
Proposition 3.1. Assume that there exists a subset of X, denoted by X̃, such that R is inde-
pendent of (S,Z) conditional on (Y, X̃) and E(S | γT0X, X̃) = E{S̃(Z; ξ∗) | γT0X, X̃}. Then,
E{U impβ (ψ0, ξ
∗)} = 0 under β = 0.
The proofs of this proposition and other technical results are provided in Chapter 3.6.1.
Remark 3.1. The missing-data mechanism assumed in this proposition may arise from the extreme-
tail sampling scheme, where only subjects with extreme values of Y are selected for measurements of
S (Lin et al. 2013). In this case, the inverse probability weighting approach is not feasible because
P (R = 1 | Y ) is zero for some subjects, whereas the imputation approach is applicable.
Remark 3.2. The dependence between R and X̃ may be introduced in the design stage, when the
sampling of S is performed separately at different values of X̃. In cancer genomics, X̃ may include
risk factors such as tumor stage and tumor grade, and subjects with unusually high or unusually low
risk may be more likely to be selected for measurements of S. In this case, X̃ is a low-dimensional
subset of X that is discrete, and a nonparametric modeling of S on X̃ is feasible.
Remark 3.3. The condition in Proposition 3.1 requires that the true and imputed S variables have
the same conditional expectation given γT0X and X̃. This condition is trivially satisfied if S is
independent of X and the imputed value has the same mean as S, as assumed by Hu et al. (2015).
For the score statistic to be unbiased, we only need the expectation of the true and imputed S
variables conditional on X̃ and a single index γT0X to be the same. This is practically achievable
via nonparametric modeling of S given the low-dimensional covariates (γT0X, X̃), even though the
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whole set of covariates X may be high-dimensional. If the missing-data mechanism does not depend
on covariates, then X̃ is absent, such that it is only necessary to correctly model the conditional
expectation of S given the single index γT0X.
Proposition 3.1 implies that the imputation score statistic is unbiased under H0 if the conditional
expectation of S given a specific projection of Z (but not necessarily the full set of Z) is correctly
specified. To guarantee that this condition holds, we model the relationship between S and
(γT0X, X̃) nonparametrically when X̃ is discrete and takes a small number of values. Because the
regression model of S on (γT0X, X̃) may not be very predictive, we include other components of Z
in the imputation model in order to improve the imputation accuracy. Given the nonparametric
function of (γT0X, X̃), the inclusion of Z will not result in bias of the score statistic even if the
imputation model is misspecified. In the sequel, we assume that the missing-data mechanism
specified in Proposition 3.1 holds and that X̃ is discrete with possible values (x̃1, . . . , x̃L). For each
x̃l (l = 1, . . . , L), we assume the working model E(S | Z, X̃ = x̃l) = gl(γT0X) + ηTl Z̃, where gl is
unspecified, and Z̃ is a specific q-dimensional function of Z that is (asymptotically) orthogonal to
(γT0X, X̃). Let (g∗l ,η∗l ) = arg min(gl,ηl) E[R{S − gl(γ
T
0X) − ηTl Z̃}2
∣∣γT0X, X̃ = x̃l] almost surely,
ξ = (g1, . . . , gL,η1, . . . ,ηL), and ξ∗ = (g∗1, . . . , g∗L,η∗1, . . . ,η∗L). The following proposition states the
unbiasedness of the resulting imputation score statistic.
Proposition 3.2. If S̃(Z; ξ∗) =
∑L




Proposition 3.2 motivates us to estimate gl and ηl using least-squares regression with the
complete observations. We propose to approximate gl (l = 1, . . . , L) with B-spline functions of order
m (De Boor 1978) and replace the true value γ0 by the estimator γ̂. For simplicity of presentation,
we assume the same set of fixed B-spline functions for each gl, but we allow them to be chosen
adaptively and separately for each gl in practice. Let m and Kn be integers, such that Kn ≥ m ≥ 2,
and Kn depends on the sample size n. For a set of grid points τ ≡ (τ0, . . . , τKn−m+1), such that
minX γ̂TX = τ0 < · · · < τKn−m+1 = maxX γ̂TX, let B(·) = (B1(·), . . . , BKn(·))T, where Bk is
the kth m-order B-spline function on τ ; the grid points at the two ends have multiplicity m. For
l = 1, . . . , L, let















where αl = (αl1, . . . , αlKn)T. Effectively, we partition the data into L strata, with each stratum corre-
sponding to a value of x̃l, and we perform separate least-squares regression for each stratum using sub-
jects with observed S. Let α̂l = (α̂l1, . . . , α̂lKn)T, ĝl =
∑Kn
k=1 α̂lkBk, and ξ̂ = (ĝ1, . . . , ĝL, η̂1, . . . , η̂L).
The robust imputation score statistic is U robβ (ψ̂, ξ̂; γ̂), where








I(X̃i = x̃l){gl(γTXi) + ηTl Z̃i}
]
,
and the third argument in U robβ (ψ, ξ;γ) corresponds to γ in the argument of gl.
Let `β(ψ, ξ;γ) be U robβ (ψ, ξ;γ) for a single subject, `ψ(ψ)[h1] be the derivative of log f(Y ;γTX, ζ)
along the path ψ = ψ0 + εh1, with h1 being a tangent vector for ψ, `βψ(ψ, ξ;γ)[h1] be the de-
rivative of `β(ψ, ξ;γ) along the same path, `ψψ(ψ)[h1,h2] be the derivative of `ψ(ψ)[h1] along
the path ψ = ψ0 + εh2, with h2 being a tangent vector for ψ, and `ξ(ξ)[h3] be the derivative of
R
∑L
l=1 I(X̃ = x̃l){S − gl(γT0X)− ηTl Z̃}2/2 along the path ξ = ξ
∗ + εh3, with h3 being a tangent
vector for ξ. Let Pn and P denote the empirical and true probability measures, respectively. We
impose the following conditions.
(C1) For l = 1, . . . , L, g∗l and η∗l are unique, and g∗l has bounded fourth derivative.
(C2) The support of Z is bounded, and γT0X has a bounded continuous support. Conditional on
Z, S has finite second moment.
(C3) The number of knots of the B-spline functions is such that K6nn−1/2 → 0 and K7nn−1/2 →∞
as n→∞.
(C4) At β = 0, ‖ζ̂ − ζ0‖ = op(n−1/4) for a suitable norm, and the estimator γ̂ satisfies
γ̂ − γ0 = Pn`∗γ(ψ0) + op(n−1/2),
where `∗γ is the efficient score function of γ, such that P`∗γ(ψ0) = 0, and P`∗γ(ψ0)`∗γ(ψ0)T is
non-zero and finite.
(C5) The functions `2β(ψ, ξ;γ0), `2ψ(ψ)[h1], `βψ(ψ, ξ;γ0)[h1], and `ψψ(ψ)[h1,h2] are Donsker for
(ψ, ξ) belonging to a neighborhood of (ψ0, ξ∗) and (h1,h2) belonging to a bounded subset
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of a suitable metric space. In addition, the information operator for the phenotype model
P`ψψ(ψ0)[·, ·] is invertible under the null hypothesis H0.
Remark 3.4. Conditions (C1) and (C2) pertain to regularity conditions on the variable with missing
values and covariates. For g∗l and η∗l to be unique, we require that Z̃ does not include X̃ and that
γT0X cannot be expressed as a function of linear terms of Z̃. In practice, we let Z̃ be a linear




i γ̂ = 0. Condition (C3)
pertains to the rate at which the number of knots of the B-spline functions increases to infinity;
particularly, the condition is satisfied with Kn = O(n1/13). Conditions (C4) and (C5) are regularity
conditions on the phenotype model, which are satisfied for common models, such as generalized linear
models and proportional hazards models. For parametric models and the Cox proportional hazards
model, the norm in condition (C4) is the Euclidean norm and the `∞[0, t∗]-norm, respectively, where
t∗ is the end of the study, and the metric space for (h1,h2) in condition (C5) is the Euclidean space
and the space of functions of bounded variation, respectively.
The asymptotic distribution of the robust imputation score statistic is given in the following theorem.
Theorem 3.1. Under conditions (C1)-(C5) and β = 0, U robβ (ψ̂, ξ̂; γ̂) is asymptotically zero-mean
normal with variance
V = P [{`β(ψ0, ξ∗;γ0)− `ψ(ψ0)[hψ]− `ξ(ξ∗)[hξ]− Iγ(γ0, ξ∗)T`∗γ(ψ0)}2],
where hψ solves P`βψ(ψ0, ξ∗;γ0)[·] = P`ψψ(ψ0)[hψ, ·], hξ = (hg,1 . . . , hg,L,hη,1, . . . ,hη,L), such
that hη,l = 0 and
hg,l(t) =
E{(1−R)I(X̃ = x̃l)A(Y,X;ψ0) | γT0X = t, X̃ = x̃l}
E{RI(X̃ = x̃l) | γT0X = t, X̃ = x̃l}






I(X̃ = x̃l)X{Rg′l(γTX)hg,l(γTX)− (1−R)A(Y,X;ψ)gl′(γTX)}
]
,
and f ′ denotes the first derivative of f for any function f .
Remark 3.5. The second and third terms in V are projections of the score function of (ψ, ξ), and
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hψ is the least-favorable direction of ψ for the phenotype model if the imputation model is assumed
to be known. The fourth term in V is present because γ̂, instead of the true value, is used in the
imputation model. The estimator γ̂ affects the imputation both by directly entering the imputation
function ĝl(γ̂TX) and by involving in the estimation of ĝl.




[{`β,i(ψ̂, ξ̂; γ̂)− `ψ,i(ψ̂)[ĥψ]− `ξ,i(ξ̂)[ĥξ]− Îγ(ψ̂, ξ̂)ˆ̀
∗
γ(ψ̂)} −M ]2,
where (`β,i, `ψ,i, `ξ,i) is (`β, `ψ, `ξ) evaluated at the observations of the ith subject, M is the sample
mean of the first term in V̂ , and (ĥψ, ĥξ, Îγ , ˆ̀
∗
γ) is the empirical version of (hψ,hξ, Iγ , `∗γ) evaluated
at (ψ̂, ξ̂). Specifically, ĥξ is obtained by performing the usual linear expansion of ξ̂ at ξ∗, with
the imputation model treated as a linear model with covariates I(X̃ = x̃l)(B(γ̂TX)T, Z̃
T)T. The
explicit form of ĥξ is given in the proof of Theorem 3.2 in Chapter 3.6.1. We formulate the variance
estimator under the linear model, the logistic model, and the Cox proportional hazards model in
Chapter 3.6.2. The resulting score test statistic is U robβ (ψ̂, ξ̂; γ̂)2/V̂ . The validity of the robust score
test is stated below.
Theorem 3.2. Under conditions (C1)-(C5) and β = 0, the empirical variance estimator V̂ converges
almost surely to the true variance V , and the test statistic U robβ (ψ̂, ξ̂; γ̂)2/V̂ converges in distribution
to the chi-square distribution with one degree of freedom.
Remark 3.6. The empirical variance estimator is consistent regardless of the missing-data mechanism
and the imputation model. By contrast, the standard model-based variance estimator with imputed
data is generally biased if the missing-data mechanism depends on the phenotype. The bias of the
standard variance estimator under generalized linear models is derived in Chapter 3.6.3.
When the missing-data mechanism does not depend on the phenotype, the score statistic is
unbiased under any imputation schemes; this result follows from the proof of Proposition 3.1. In
this case, the proposed test is not required for bias correction, and one may wonder whether the
inclusion of the B-spline terms and the stratification may lead to power loss; however, for the linear
model, the asymptotic power of the proposed test is higher than or equal to that of the score test
without the B-spline terms or stratification. The comparison of power between the proposed test
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and the standard score test is difficult under more general settings because the power generally
depends on the missing-data mechanism and high moments of S. The derivation for the power of
the proposed test is given in Chapter 3.6.4.
3.3 Simulation Studies
Let X = (X1, X2, X3)T, where X1, X2, and X3 are independent standard normal, Bernoulli(0.5),
and Binomial(2, 0.25), respectively. Let G be a vector of other covariates that are used to predict S.
In particular, G = (G1, . . . , G4), where Gj (j = 1, . . . , 4) is independent Binomial(2, 0.3). In cancer
genomics, X1, X2, and X3 may represent (standardized) age, gender, and tumor stage, respectively,
andG may represent genotypes at four loci. We generated the phenotype Y using the linear predictor
r(S,X) = γ0 + γTX + βS under the linear, logistic, and proportional hazards models. For all
models, we set γ = (1,−1, 0.5)T. For the linear model, we generated Y ∼ N{r(S,X), 1} with γ0 = 0.
For the logistic model, we set logit−1{P (Y = 1 | S,X)} = r(S,X), where γ0 was chosen such that
P (Y = 1) ≈ 0.15. For the proportional hazards model, we generated Y with the hazard function
λ(t | S,X) = 0.5ter(S,X) and γ0 = 0. The censoring variable was generated independently from
Unif(0, τ), where τ was chosen such that the censoring proportion was about 40%. We considered
two models for S: with Model 1, S = X1 +X2 + 0.3X3 + 0.4(G1 −G2 +G3 −G4) + N(0, 1); and
with Model 2, S = (X1 +X2) + 0.1(X1 +X2)2 + 0.3I(X3 = 2) + 0.4(G1 −G2 +G3 −G4) + N(0, 1).
We compared the performance of six tests: (1) the standard score test using complete data only;
(2) the standard score test with missing values imputed under a linear model of S on Z ≡ (XT,GT)T;
(3) Lawless (2016)’s score test based on the same model of S as (2); (4) Hu et al. (2015)’s score test
with the imputed data of (2); (5) the proposed score test with stratification variable X̃ = X2 and Z̃
being that specified in Remark 3; and (6) the imputation score test with missing data imputed using
a linear model of S on Z = (XT, X21 , X1X2, I(X3 = 2),GT)T and the empirical variance estimator.
We refer to methods (1)-(6) as the complete-case analysis, the simple imputation method, Lawless’
method, Hu’s method, the proposed imputation method, and the full-model imputation method,
respectively. The last method is the gold standard but is not practical because it requires correct
specification of a complex missing-data model. Derkach et al. (2015)’s method was not included
because it requires the covariates in the imputation model to be discrete and is identical to Lawless
(2016)’s method when a linear imputation model is assumed. Note that the missing-data models
used by all the methods are correct under Model 1, but only the missing-data model used by the
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full-model imputation method is correct under Model 2. For the proposed imputation method,
we chose the degree and number of knots of the B-spline functions using five-fold cross-validation
separately for each stratum. For the lth stratum, the grid point τk (k = 1, . . . ,Kn − m − 2)
was set to be the empirical k/(Kn −m + 1)-quantile of γ̂TXi among subjects with Ri = 1 and
Xi = x̃l, τ0 = minX̃i=x̃l γ̂
TXi, and τKn−m−1 = maxX̃i=x̃l γ̂
TXi. Lawless’ and Hu’s methods are
not applicable to the survival phenotype.
We considered two missing-data mechanisms. Mechanism 1 is missing completely at random,
where the missing-data status is independent of other variables. For Mechanism 2, the missing-data
status was generated separately for two subsets of subjects: one subset consisted of all subjects with
X2 = 1, and a random sample of subjects from the subset were selected for observation of S; the
other subset consisted of all subjects with X2 = 0, and subjects from the subset were selected for
observation of S based on the phenotype. For the continuous and survival phenotypes, an equal
number of subjects at the two extreme tails of the phenotype distribution were selected. For the
binary phenotype, all subjects with Y = 1 were selected, and sufficient subjects with Y = 0 were
selected such that the desired missing proportion was attained. The missing proportion was set to
be the same between the two subsets of subjects. This setting mimics a study where two datasets
with different sampling schemes are combined.
We considered a sample size of 1,500 and missing proportions ranging from 30% to 60%. For
each setting, we simulated 1,000,000 and 100,000 replicates for β = 0 and β 6= 0, respectively. The
nominal significance level was set to 10−3. We plot the rejection probability against the missing
proportion for the two models of S and the two missing-data mechanisms; see Figures 3.1–3 for the
results of the linear, logistic, and Cox proportional hazards models, respectively.
Under Mechanism 1, all methods have correct type I error. Under Model 1 and Mechanism 2,
the simple imputation method has inflated type I error because the variance of the score statistic is
underestimated. The complete-case analysis is also invalid except for the binary phenotype, but
the type I error inflation is not as severe; the complete-case analysis for the binary phenotype has
correct type I error because of the special structure of the logistic model (Prentice and Pyke 1979).
Hu et al. (2015)’s variance estimator requires that both the actual and imputed S variables are
independent of X, which does not hold under either Model 1 or Model 2. As a result, the variance
is overestimated under Mechanism 2, which leads to type I error deflation. The remaining methods
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Complete cases Simple imputation Lawless Hu Proposed imputation Full−model imputation
 β = 0
 β = 0.1
Figure 3.1. Rejection Probabilities Under the Null and Alternative Hypotheses for the Continuous
Phenotype.
have consistent variance estimators and, therefore, have correct type I error. Under Model 2 and
Mechanism 2, the score statistics of the complete-case analysis and the methods based on a model
of S on linear terms of X are generally biased, giving rise to type I error inflation in most cases.
Hu’s method exhibits type I error deflation under the logistic model because the bias of the score
statistic is offset by the overestimation of the variance in this specific setting. (Because the absolute
bias of the score statistic tends to infinity as n→∞, Hu’s method would yield type I error inflation
for large enough sample size.) The proposed imputation method is valid even though the imputation
model is misspecified because the score statistic is unbiased. The full-model imputation method is
also valid because the imputation model is correct.
The power of the complete-case analysis is generally low because it discards useful information.
Under Model 1 or Mechanism 1, all valid methods that use the whole dataset have similar power.
Under Model 2 and Mechanism 2, the full-model imputation method is the most powerful among
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Model 2, Mechanism 2
Complete cases Simple imputation Lawless Hu Proposed imputation Full−model imputation
 β = 0
 β = 0.31
Figure 3.2. Rejection Probabilities Under the Null and Alternative Hypotheses for the Binary
Phenotype.
the valid methods because a correct imputation model is assumed. However, this method cannot
be used in practice because it requires knowledge of the true relationship between S and Z. The
proposed imputation method is only slightly less powerful than the full-model imputation method.
The bias of the score statistic of the other methods can lead to substantially low power.
3.4 Real Data Analysis
We analyzed a dataset of patients with serous ovarian cancer from TCGA (The Cancer Genome
Atlas Research Network 2011). In the study, most subjects had available genomic data, including
data on DNA copy number, somatic mutation, and levels of expression of mRNA measured by
microarray platforms. Only a subset of subjects had enough tissue sample left for RNA sequencing,
which was introduced after the study had begun. Demographic and clinical variables, including
age at diagnosis, tumor stage, tumor grade, time to tumor progression, and time to death, were
available for most subjects. The median follow-up time was about 2.5 years, and roughly 30% of
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Complete cases Simple imputation Proposed imputation Full−model imputation
 β = 0
 β = 0.13
Figure 3.3. Rejection Probabilities Under the Null and Alternative Hypotheses for the Survival
Phenotype.
the patients were lost to follow-up before tumor progression or death. The data are available at
http://gdac.broadinstitute.org/.
We focused on testing the association between mRNA expression, measured by RNA sequencing,
and progression-free survival time. We used the Fragments Per Kilobase of transcript per Million
mapped reads (FPKM) values for the mRNA expression variable. The number of transcripts with
RNA sequencing data was about 57,000. We considered a subset of 9,068 genes that were mutated
in samples from more than five subjects. The number of subjects with available mutation, copy
number, and clinical data was 407, approximately 30% of whom did not have RNA sequencing data.
We fit the Cox model for progression-free survival and included age, tumor stage, tumor grade,
the squared term of age, the interaction between age and (dichotomized) tumor stage, and the
interaction between age and (dichotomized) tumor grade as covariates. The predictors in the



























































































Figure 3.4. Quantile-Quantile Plots for the RNA-Seq Analysis of the TCGA Ovarian Cancer Data.
The left plot shows the results for the original data, and the right plot shows the results with the
missing proportion increased to 60%. The p-values are truncated at 10−10.
together with somatic mutation, copy number, and mRNA microarray expression. Microarray
mRNA expression and somatic mutation were excluded from the imputation model if they were
missing or too sparse. We did not include a stratification variable. The B-spline functions were
selected in the same way as in the simulation studies. For comparison, we performed the standard
score test with only the complete cases and with the missing values imputed under a linear model.
For further illustration, we performed the proposed test and the standard score test on the dataset
with the missing proportion increased to 60%, where the RNA sequencing variables for subjects
with intermediate survival or censoring time were treated as missing. The quantile-quantile plots
are shown in Figure 3.4.
For the original dataset, the p-values from the proposed method agree with the expectation that
most gene expressions are not associated with progression-free survival. The complete-case analysis
and the simple imputation method yielded excessive false-positive signals because the standard
variance estimates of the score statistic are smaller than the empirical variance. With extra missing
data, the inflation of type I error is more severe for the simple imputation method, whereas the
type I error is preserved by the proposed method.
The top ten genes identified by the proposed method from the original data are presented
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Table 3.1. Top Genes and Their p-values in the RNA-Seq Analysis of the TCGA Ovarian Cancer
Data.
Gene Proposed method Complete cases Single imputation
WDR91 4.85E-05 3.20E-04 2.65E-05
SLC4A8 7.60E-05 7.77E-05 1.08E-05
NPAS3 2.15E-04 9.11E-04 1.98E-04
PLAUR 2.44E-04 5.38E-03 9.40E-04
TGFBI 2.68E-04 5.90E-05 6.32E-05
ST3GAL1 3.57E-04 9.57E-03 3.30E-03
LRIG2 3.88E-04 4.31E-03 1.42E-04
DUSP1 4.03E-04 1.26E-03 2.63E-03
GALNT6 6.27E-04 1.87E-03 2.25E-04
VMO1 6.63E-04 9.06E-02 4.24E-03
in Table 3.1. Several of them have been reported to be related to ovarian cancer (Denkert et al.
2002; Wang et al. 2005; Ahmed et al. 2007; Ween et al. 2012; Arend et al. 2013; Wang et al.
2014; Killeen et al. 2014; Caburet et al. 2015). Among those genes, the associations between
progression-free survival time and the expressions of WDR91, SLC4A8, NPAS3, PLAUR, ST3GAL1,
LRIG2, DUSP1, GALNT6, and VMO1 are more significant under the proposed method than under
the complete-case analysis. The significance levels for associations between progression-free survival
time and expressions of of PLAUR, ST3GAL1, DUSP1, and VMO1 are lower under the simple
imputation method than the proposed method.
3.5 Discussion
In this chapter, we propose a robust score test for the association between a phenotype and a
genomic variable with partially missing values. The test is based on a semiparametric model for the
genomic variable, where the semiparametric component ensures that under the null hypothesis, the
score statistic with imputed values is unbiased for general missing-data mechanisms and arbitrary
distributions of the genomic variable. Because the nonparametric function in the imputation model
is one-dimensional regardless of the dimension of the covariates, the score test is computationally
feasible with a large number of covariates. In addition to correcting for the bias of the score statistic,
the semiparametric component results in a better fit of the imputation model, which leads to power
gain even when data are missing completely at random. When the missing-data mechanism depends
on the phenotype, the proposed test has correct type I error, whereas the standard score test is
generally invalid. When the missing-data mechanism is independent of the phenotype, both the
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proposed and standard score tests have correct type I error, but the proposed test is asymptotically
more powerful.
The validity of the proposed test follows from two special properties of the score statistic
under the null hypothesis. First, the phenotype model does not involve the variable with missing
values, and the score statistic derived under the full likelihood coincides with the imputation score
statistic. Second, the score statistic is mean zero if the expectations of the actual and imputed values
conditional on a low-dimensional function of the covariates are equal. As a result, single imputation
yields a valid score statistic if the expectation of the variable with missing values conditional on the
low-dimensional function of the covariates is correctly specified. These two properties do not hold
under the alternative hypothesis, making parameter estimation with missing data a much more
challenging problem than hypothesis testing. For estimation, single imputation generally yields
underestimation of standard errors (Little 1992), and a correct specification of the missing-data
model is required for valid inference.
Our work can be extended in several directions. First, we have focused on a continuous genomic
variable that is either exactly observed or missing. We may allow for a binary or categorical
variable by incorporating the proposed semiparametric component into a generalized linear modeling
framework. We may also consider genomic variables that are subject to censoring or detection
limits, as in the case of metabolomics data (Yu et al. 2014). In this case, the conditional mean of
the genomic variable cannot be consistently estimated using simple least-squares estimation, and
additional assumptions on the distribution of the genomic variable are necessary.
Second, it would be of interest to perform a joint test for multiple genomic variables, where each
variable may have a separate pattern of missing values. This extension can be applied to many
existing testing procedures that involve a multivariate score statistic, such as the sequence kernel
association test for rare variants (Wu et al. 2011), tests for meta-analysis of sequencing data (Tang
and Lin 2013), and the joint test for multiple genomic variables (Huang et al. 2014). Joint modeling
of multiple variables with missing values is more challenging than modeling a single variable with
missing value, when the pattern of the missing values for each variable do not overlap. Nevertheless,
fitting a separate imputation model for each variable is not preferable, as it results in efficiency loss
when the variables are correlated.
Finally, we have assumed that the missing-data mechanism depends only on the phenotype and
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a set of discrete covariates. The methodology can be extended to allow the missing-data mechanism
to depend on continuous covariates by relating the variable with missing values to a nonparametric
function of the phenotype and covariates. In addition, we may consider a missing-data mechanism
that depends on a different phenotype; this scenario is common in the analysis of secondary
phenotypes. In this case, the function through which the covariates affect the alternative phenotype
must be estimated, and the variable with missing values should be modeled nonparametrically on
that function.
3.6 Technical Details and Additional Results
3.6.1 Proofs of Technical Results
In this section, we prove the two propositions and the two theorems put forth in Chapter 3.2.
Proof of Proposition 3.1. The expected value of U impβ (ψ0, ξ
∗) is
E[A(Y,X;ψ0){RS + (1−R)S̃(Z; ξ∗)}]
= E[A(Y,X;ψ0)R{S − S̃(Z; ξ∗)}] + E{A(Y,X;ψ0)S̃(Z; ξ∗)}
= E[A(Y,X;ψ0)RE{S − S̃(Z; ξ∗) | Y,γT0X, X̃}]
= E[E{A(Y,X;ψ0)R | γT0X}E{S − S̃(Z; ξ∗) | γT0X, X̃}],
where the second and third equalities follow from the facts that Y is independent of Z conditional
on X and that R is independent of (S,Z) conditional on (γT0X, X̃), respectively. Clearly, the
above expectation is zero since E(S | γT0X, X̃) = E{S̃(Z; ξ∗) | γT0X, X̃}.
Proof of Proposition 3.2. Because S is independent of R conditional on (γT0X, X̃) under β = 0,
E
[
R{S − gl(γT0X)− ηTl Z̃}2
∣∣γT0X, X̃ = x̃l]
= E(R | γT0X, X̃ = x̃l)E
[
{S − gl(γT0X)− ηTl Z̃}2
∣∣γT0X, X̃ = x̃l]
= E(R | γT0X, X̃ = x̃l)E
(
[S − {gl(γT0X) + ηTl E(Z̃ | γT0X, X̃ = x̃l)}
−ηTl {Z̃ − E(Z̃ | γT0X, X̃ = x̃l)}]2
∣∣γT0X, X̃ = x̃l).
Therefore, (g∗l ,η∗l ) satisfies g∗l (t) + η∗Tl E(Z̃ | γT0X = t, X̃ = x̃l) = E(S | γT0X = t, X̃ = x̃l). The
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mean of the imputed S is
E{S̃(Z; ξ∗) | γT0X, X̃} =
L∑
l=1




I(X̃ = x̃l)E(S | γT0X, X̃ = x̃l)
= E(S | γT0X, X̃).
The desired result follows from Proposition 3.1.
Before proving Theorem 3.1, we present the following lemma, which pertains to the consistency
of ξ̂.
Lemma 3.1. Under conditions (C1)-(C4), ‖ĝl − g∗l ‖W 1,∞ → 0, and ‖ĝl − g∗l ‖2L2(X) + ‖η̂l − η
∗
l ‖22 =
op(n−1/2) for l = 1, . . . , L, where for any function h that has bounded first derivative, ‖h‖W 1,∞ =
‖h‖`∞ + ‖h′‖`∞, and ‖h‖L2(X) = [E{h(γT0X)2}]1/2.
Proof of Lemma 3.1. By Theorem 6.25 of Schumaker (2007), there exists g̃l =
∑Kn
k=1 α̃lkBk, such
that ‖g̃l− g∗l ‖W 1,∞ ≤ O(K−2n ) and ‖g̃l− g∗l ‖L2 ≤ O(K
−7/2
n ) for each l = 1, . . . , L. Let φl(gl,ηl;γ) =
−RI(X̃ = x̃l){S−gl(γTX)−ηTl Z̃}2/2. By the definition of (ĝl, η̂l), Pnφl(ĝl, η̂l; γ̂) ≥ Pnφl(g̃l,η∗l ; γ̂).
By the concavity of φl,
Pnφl(εĝl + (1− ε)g̃l, εη̂l + (1− ε)η∗l ; γ̂) ≥ Pnφl(g̃l,η∗l ; γ̂),
where ε = (1 +
∑Kn
k=1 |α̂lk − α̃lk|+
∑q
j=1 |η̂lj − η∗lj |)−1. Therefore,
(Pn − P ){φl(εĝl + (1− ε)g̃l, εη̂l + (1− ε)η∗l ; γ̂)− ψ(g̃l,η∗l ; γ̂)}
≥ −P{φl(εĝl + (1− ε)g̃l, εη̂l + (1− ε)η∗l ; γ̂)− φl(g̃l,η∗l ; γ̂)}. (3.1)
Note that















where the first inequality follows because α̃lk is bounded, and γ̃ is some value between γ0 and γ̂.
Likewise, because
εα̂lk + (1− ε)α̃lk =
α̂lk − α̃lk
c0 + |α̂lk − α̃lk|
+ 1 + |α̂lk − α̃lk|
c0 + |α̂lk − α̃lk|
α̃lk
for some c0 > 1,
φl(εĝl + (1− ε)g̃l, εη̂l + (1− ε)η∗l ; γ̂)− φl(εĝl + (1− ε)g̃l, εη̂l + (1− ε)η∗l ;γ0) ≤ Op(Knn−1/2).
Therefore, (3.1) implies that
(Pn − P ){φl(εĝl + (1− ε)g̃l, εη̂l + (1− ε)η∗l ;γ0)− φl(g̃l,η∗l ;γ0)}+Op(Knn−1/2)
≥ −P{φl(εĝl + (1− ε)g̃l, εη̂l + (1− ε)η∗l ;γ0)− φl(g̃l,η∗l ;γ0)}. (3.2)
By Theorem 2.6.15 of van der Vaart and Wellner (1996), referred to as VW hereafter, {{ηTl Z̃ +∑Kn
k=1 αlkBk(γT0X)}2 : maxk,j(|αlk|, |ηlj |) < M} is a Vapnik-Chervonenkis (VC) class with VC index
at most (Kn + q)2 + 2 for any M <∞. By Theorem 2.6.7 of VW, we show that





for any 0 ≤ c1 ≤ 1, where N is the covering number, c2 is a constant, F = {φl(gl,ηl;γ0) : gl(·) =∑Kn
k=1 αlkBk(·),maxk,j(|αlk|, |ηlj |) < M}, and F is an envelope function of F that consists of second-
order terms of (S, Z̃). Therefore, the uniform entropy of the class of functions is O(K2n). By
Theorem 2.14.1 of VW and Markov’s inequality, the left-hand side of (3.2) is Op(Knn−1/2).






P (X̃ = x̃l)E[E(R | γT0X, X̃ = x̃l){g̃l(γT0X)− g∗l (γT0X)}2 | X̃ = x̃l]
≤ Pφl(g∗l ,η∗l ;γ0) +Op(‖g̃l − g∗l ‖2L2(X))
≤ Pφl(g∗l ,η∗l ;γ0) +Op(K−7n ),
where the first equality above follows because R and S are conditionally independent given γT0X
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and X̃. Likewise,
Pφl(εĝl + (1− ε)g̃l, εη̂l + (1− ε)η∗l ;γ0)





P (X̃ = x̃l)




‖ĝl − g̃l‖2L2(X) +
q∑
j=1
|η̂lj − η∗lj |2
)
≤ Op(Knn−1/2) +Op(K−7n ).
Because ‖ĝl − g̃l‖2L2(X) ≥ c3
∑Kn
k=1 |α̂lk − α̃lk|2 for some c3 > 0,
Kn∑
k=1
|α̂lk − α̃lk|2 +
q∑
j=1

















|α̂lk − α̃lk|2 +
q∑
j=1





k=1 |α̂lk − α̃lk|2 +
∑q
j=1 |η̂lj − η∗lj |2 ≤ Op(K3nn−1/2) +Op(K−5n )}. Note that
‖ĝl − g̃l‖W 1,∞ ≤ maxx Bk(x)
Kn∑
k=1













= Op(K3nn−1/4 +K−1n ).
Because K6nn−1/2 → 0, both ‖ĝl − g∗l ‖W 1,∞ and
∑q
j=1 |η̂lj − η∗lj |2 converge to zero in probability.
To establish the rate of convergence, we replace ε by 1 in (3.2). The left-hand side of the resulting
inequality is op(n−1/2) because φl(gl,η∗l ;γ0) is Donsker in a neighborhood of g∗l . By the linear
expansion on the right side,
op(n−1/2) ≥ Op(K−7n ) + ‖ĝl − g∗l ‖2L2(X) +
q∑
j=1
|η̂lj − η∗lj |2.
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The desired rate of convergence follows since K7nn−1/2 →∞.
Proof of Theorem 3.1. The imputation score statistic is
n1/2Pn`β(ψ̂, ξ̂; γ̂)
= n1/2Pn`β(ψ0, ξ∗;γ0) + n1/2P`β(ψ̂, ξ̂; γ̂) + n1/2(Pn − P ){`β(ψ̂, ξ̂; γ̂)− `β(ψ0, ξ∗;γ0)}
= n1/2Pn`β(ψ0, ξ∗;γ0) + n1/2P{`β(ψ̂, ξ∗; γ̂)− `β(ψ0, ξ∗;γ0)}
+n1/2P{`β(ψ0, ξ̂;γ0)− `β(ψ0, ξ∗;γ0)}+ op(1). (3.3)
The second equality above follows because the convergence rate of (ψ̂, ξ̂) is at least n−1/4 and
`β(ψ, ξ;γ) is Donsker over a neighborhood of (ψ0, ξ∗,γ0). By the linear expansion, the second term






I(X̃ = x̃l)g∗′0 (γT0X)XT
}
(γ̂ − γ0) + n1/2P`βψ(ψ0, ξ∗;γ0)[ψ̂ −ψ0],
up to an op(1) term. Let I(1)γ (ψ, ξ) = −E{A(Y,X;ψ)(1−R)
∑L
l=1 I(X̃ = x̃l)g′l(γTX)X}. Clearly,
the first term of the above expression is −n1/2I(1)γ (ψ0, ξ∗)TPn`∗γ(ψ0) + op(1) by condition (C4). By
condition (C5), hψ exists, and the second term of the above expression is equal to n1/2Pn`ψ(ψ0)[hψ]+
op(1).






I(X̃ = x̃l){ĝl(γT0X)− g∗l (γT0X) + (η̂l − η∗0)TZ̃}
]
.
Let `g,l(gl,ηl;γ)[hg,l] ≡ RI(X̃ = x̃l){S − gl(γTX)− ηTl Z̃}hg,l(γTX) and `η,l(gl,ηl;γ) ≡ RI(X̃ =
x̃l){S− gl(γTX)−ηTl Z̃}Z̃ be the score function for gl and ηl, respectively. Let h̃g,l be the B-spline
approximation of hg,l on the same grid as ĝl. By the definition of ĝl and η̂l,
(Pn − P ){`g,l(ĝl, η̂l; γ̂)[h̃g,l] + hTη,l`η,l(ĝl, η̂l; γ̂)} = −P{`g,l(ĝl, η̂l; γ̂)[h̃g,l] + hTη,l`η,l(ĝl, η̂l; γ̂)}.
Because ĝl and h̃g,l have bounded first derivatives and `g,l and `η,l are differentiable, `g,l(gl,ηl;γ)[hg,l]
and `η,l(gl,ηl;γ) are Donsker in a neighborhood of (g∗l ,η∗l ,γ0, hg,l). By the Donsker property of
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the `g,l and `η,l and the consistency results of Lemma 3.1,
(Pn − P ){`g,l(g∗l ,η∗l ;γ0)[hg,l] + hTη,l`η,l(g∗l ,η∗l ;γ0)}
= E[RI(X̃ = x̃l)g∗′l (γT0X){hg,l(γT0X) + hTη,lZ̃}XT](γ̂ − γ0)
+E[RI(X̃ = x̃l){hg,l(γT0X) + hTη,lZ̃}{ĝl(γT0X)− g∗l (γT0X) + (η̂l − η∗l )TZ̃}] + op(n−1/2).
Thus,
E[RI(X̃ = x̃l){hg,l(γT0X) + hTη,lZ̃}{ĝl(γT0X)− g∗l (γT0X) + (η̂l − η∗l )TZ̃}]
= (Pn − P )
{
`g,l(g∗l ,η∗l ;γ0)[hg,l] + hTη,l`η,l(g∗l ,η∗l ;γ0)
−E[RI(X̃ = x̃l)g∗′l (γT0X){hg,l(γT0X) + hTη,lZ̃}XT]`∗γ(ψ0)
}
+ op(n−1/2).
It is easy to see that hg,l and hη,l solve
E[RI(X̃ = x̃l){hg,l(γT0X) + hTη,lZ̃}w(γT0X, Z̃)]
= E[(1−R)I(X̃ = x̃l)A(Y,X;ψ0)w(γT0X, Z̃)] (3.4)
for all w ∈ {w(t, Z̃) = w1(t) +wT2 Z̃ : w1 has bounded fourth derivatives,w2 ∈ Rq}. Therefore,




{`g,l(g∗l ,η∗l ;γ0)[hg,l] + hTη,l`η,l(g∗l ,η∗l ;γ0)} − I(2)γ (ψ0, ξ∗)T`∗γ(ψ0)
]
+ op(1)
= n1/2Pn{`ξ(ξ∗)[hξ]− I(2)γ (ψ0, ξ∗)T`∗γ(ψ0)}+ op(1),
where I(2)γ (ψ, ξ) =
∑L
l=1 E[RI(X̃ = x̃l)g′l(γTX){hg,l(γTX) + h
T
η,lZ̃}X]. The desired result follows
with Iγ(ψ, ξ) = I(1)γ (ψ, ξ) + I(2)γ (ψ, ξ).
Proof of Theorem 3.2. Under condition (C5), `2β(ψ, ξ), `2ψ(ψ)[h1], `2ξ(ξ)[h2], and `
∗2
γ (ψ) are Glivenko-
Cantelli classes over the space of (ψ, ξ,h1,h2). Thus, the variance estimator V̂ is consistent if
(ψ̂, ξ̂, ĥψ, ĥξ) are consistent. The consistency of (ψ̂, ξ̂) follows from Lemma 3.1 and condition (C4).
A consistent estimator of hψ can be obtained by solving Pn`ψψ(ψ̂)[hψ,ψ] = Pn`βψ(ψ̂, ξ̂; γ̂)[ψ]
for all ψ. The estimator ĥξ ≡ (ĥg,1, . . . , ĥg,L, ĥη,1, . . . , ĥη,L) is obtained by solving the empirical
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version of (3.4) for the B-spline approximation of the function w. Specifically, ĥg,l =
∑Kn
k=1 θ̂lkBk for
l = 1, . . . , L, such that θ̂l ≡ (θ̂l1, . . . , θ̂lKn) and ĥη,l solve
Pn
[












A(Y,X; ψ̂)(1−R)I(X̃ = x̃l)Z̃
}
for j = 1, . . . ,Kn. By the Glivenko-Cantelli properties of the functions involved in the above
equations and the consistency of ψ̂ and the B-spline approximations, ĥξ → hξ. The asymptotic
distribution of the test statistic follows from Slutsky’s theorem.
We show that the resulting projection `ξ(ξ∗)[ĥξ] is the same as that obtained by treating
the B-spline terms as fixed covariates. Let Z(R)l and Z
(1−R)
l be matrices formed by stacking
(B(γ̂TXi)T, Z̃
T
i ) together for subjects with I(X̃i = x̃l, Ri = 1) = 1 and I(X̃i = x̃l, Ri = 0) = 1,
respectively, and let A(1−R)l be a vector with elements A(Yi,Xi; ψ̂) for subjects with X̃i = x̃l and










Let Z li(γ) = I(X̃i = x̃l)(B(γTXi)T, Z̃
T
i )T and Z l be the generic variable. The projection of the


























RiI(X̃i = x̃l)Z li(γ̂)Z li(γ̂)T
}−1
Z l(γ0),
which is the projection of the score of ξ, with Z li treated as a set of fixed covariates.
3.6.2 Explicit Forms of Variance Estimators
In this section, we formulate the variance estimators for the linear model, the logistic model,
and the Cox proportional hazards model. Let Zi(γ) ≡ (Z1i(γ)T, . . . ,ZLi(γ)T)T denote the
vector of predictors of S, with Z li(γ) defined in the proof of Theorem 3.2. Let ξ denote the
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corresponding regression parameter and ξ̂ denote the least-squares estimator of ξ. Let Z(γ) ≡
(Z1(γ)T, . . . ,ZL(γ)T)T be the generic version of Zi(γ). The robust imputation score statistic is
U robβ (ψ̂, ξ̂; γ̂) = n−1/2
n∑
i=1
`β,i(ψ̂, ξ̂; γ̂) = n−1/2
n∑
i=1




`ξ,i(ψ, ξ) = Ri{Si − ξTZi(γ)}Zi(γ)
Iξγ(ψ, ξ) = −E{RZ(γ)ξTZ(1)(γ)XT}
Iξξ(ψ, ξ) = −E{RZ(γ)Z(γ)T}
Iβξ(ψ, ξ) = E{(1−R)A(Y,X;ψ)Z(γ)},




l (γ) = (I(X̃ = x̃l)B′l(γTX)T,0Tq )T for l = 1, . . . L,
the derivative B′ is defined component-wise, and 0q is a q-vector of zeros.
First, we consider the linear and logistic models. For the linear model, we redefine A(Y,X;ψ) =
Y − γTX, where the error variance is omitted because it only acts as a scaling factor. For the two
models, there is no nuisance parameter ζ, and ψ = γ. Let
`GLMγ,i (γ, ξ) = A(Yi,Xi;γ)Xi,
IGLMγγ (γ, ξ) = E{A(1)(X;γ)XT}
IGLMβγ (γ, ξ) = E[A(1)(X;γ)T{RS + (1−R)ξTZ(γ)}+ (1−R)A(Y,X;γ)ξTZ(1)(γ)XT],
where A(1)(X;γ) = −X for the linear model, and A(1)(X;γ) = −eγTX/(1 + eγTX)2X for the
logistic model. In the sequel, we may omit the arguments of the above functions. The variance


























ξ) is the sample mean of (`β,i, `GLMψ,i , `ξ,i), and (Î
GLM
γγ , Îξγ , Îξξ, Î
GLM
βγ , Îβξ) is the
empirical version of (IGLMγγ , Iξγ , Iξξ, IGLMβγ , Iβξ).
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For the Cox proportional hazards model, let









for r = 0, 1, and 2, where a⊗0 = 1, a⊗1 = a, and a⊗2 = aaT for any vector a. Partition
K(1) = (K(1)T1 ,K
(1)
2 )T with K
(1)
1 ∈ Rq×1 and K
(1)
2 ∈ R and K(2) into K
(2)
11 ∈ Rq×q, K
(2)
12 ∈ Rq×1,
K(2)21 ∈ R1×q, and K
(2)
22 ∈ R. Let















K(1)1 (T̃j ;γ, ξ)
K(0)(T̃j ;γ, ξ)
}














K(1)2 (T̃j ;γ, ξ)
K(0)(T̃j ;γ, ξ)
}
ICOXβγ (ψ, ξ) = E[{∆− Λ(T̃ )eγ
TX}(1−R)ξTZ(1)(γ)XT] + v12(γ, ξ)T
ICOXγγ (ψ, ξ) = v11(γ, ξ),
where




jk (T̃ ;γ, ξ)T
K(0)(T̃ ;γ, ξ)
−
K(1)j (T̃ ;γ, ξ)K
(1)
k (T̃ ;γ, ξ)T
K(0)(T̃ ;γ, ξ)2

 for j, k = 1 or 2.











γγ )−1(`COXγ,i − ¯̀
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γγ ) is the empirical version of (ICOXβγ ICOXγγ ).
3.6.3 Bias of the Standard Variance Estimator
In this section, we evaluate the standard model-based variance estimator based on imputed data.
Consider a generalized linear model with no nuisance parameter. The information matrix of (β,γ)





where B(X;γ) = Var{A(Y,X;γ) |X}. The limit of the model-based variance estimator with the
imputed data is equal to
V̂ std = E[B(X;γ0){S̃2 − E(S̃X)TE(XXT)−1S̃X}]
= E{B(X;γ0)S̃2} − E{B(X;γ0)SXT}E{B(X;γ0)XXT}−1E{B(X;γ0)SX},
where S̃ is equal to S if R = 1 and is equal to S̃(Z; ξ∗) otherwise.
We derive the bias of the model-based variance estimator under a correct imputation model, i.e.,
E(S |X) = E{S̃(Z; ξ∗) |X}, and a balanced sampling scheme of S, i.e., E{A(Y,X;γ0)R |X} = 0.
Assume that supZ |S̃(Z; ξ̂)− S̃(Z; ξ∗)| = Op(n−1/2). In this case, the imputation score statistic is








A(Yi,Xi;γ0)S̃i −B(Xi;γ0)S̃iXTi (γ̂ − γ0)




A(Yi,Xi;γ0)[S̃i − E{B(X;γ0)S̃XT}E{B(X;γ0)XXT}−1Xi] + op(1),
where the third equality follows from the rate of convergence of S̃(Z; ξ̂) and the balanced sampling
scheme. Therefore, the asymptotic variance of the imputation score statistic is
E{A(Y,X;γ0)2S̃2} − E{B(X;γ0)SXT}E{B(X;γ0)XXT}−1E{B(X;γ0)SX}.
The bias of the model-based estimator is
E{B(X;γ0)S̃2} − E{A(Y,X;γ0)2S̃2}. (3.5)
Let vY,j(X) = Var{A(Y,X;γ) | R = j,X}, pR(X) = P (R = 1 | X), vS(X) = E(S2 | X), and
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vS̃(X) = E{S̃(Z; ξ
∗)2 |X}. The first term of (3.5) is E{B(X;γ0)pR(X)vS(X)}+ E[B(X;γ0){1−
pR(X)}vS̃(X)]. By the definition of B(X;γ0),
B(X;γ0) = Var{A(Y,X;γ0) |X}
= E[Var{A(Y,X;γ0) |X, R} |X] + Var[E{A(Y,X;γ0) |X, R} |X]
= pR(X)vY,1(X) + {1− pR(X)}vY,0(X).
The second term of (3.5) is
E[A(Y,X;γ0)2{RS + (1−R)S̃(Z; ξ∗)}2]
= E{A(Y,X;γ0)2RS2}+ E{A(Y,X;γ0)2(1−R)S̃(Z; ξ∗)2}
= E[vY,1(X)pR(X)vS(X)}+ E{vY,0(X){1− pR(X)}vS̃(X)].
To see that (3.5) is non-zero in general, consider the simple case of X = 1, vY,1 > vY,0, and
vS > vS̃ , such that there is no covariate, the variance of the phenotype is larger among subjects with
observed S, and the variance of the true S is larger than that of the imputed S. By Chebyshev’s sum
inequality, the true variance E{A(Y,X;γ0)2S̃2} is strictly larger than the limit of the model-based
variance estimator E{B(X;γ0)2S̃2}. By contrast, if the missing-data mechanism does not depend
on Y , then vY,1 and vY,0 are equal. As a result, (3.5) is equal to zero, and the model-based variance
estimator is consistent.
3.6.4 Evaluation of Power
In this section, we evaluate the power of the imputation score test under the linear model:
Y = γTX + βS + N(0, σ2). Assume the same imputation model for S as in Chapter 3.6.2 with
a general predictor Z(γ). Assume also that X is contained in Z(γ) and that E(S | γT0X, X̃) =
E{ξ∗TZ(γ0) | γT0X, X̃}, such that the score statistic is unbiased. The missing-data status can be
expressed as R = I{(Y, X̃) ∈ Ω(ω)}, where for every fixed ω, Ω(ω) is a deterministic subset of the
space of (Y, X̃), and ω is a random variable that is independent of (Y,Z(γ), S). Adopting the notation
introduced in Chapter 3.6.2, the score statistic can be expanded as n−1/2
∑n
i=1 Ψ(`β,i, `Tγ,i, `Tξ,i)T,
where Ψ = (1, (Iβγ − ITβξI−1ξξ Iξγ)I
−1
γγ ,−IβξI−1ξξ ), `γ,i = `
GLM
γ,i , Iγγ = IGLMγγ , and Iβγ = IGLMβγ .







= n1/2E[(Y − γT0X){RS + (1−R)ξ∗TZ(γ0)}]
= n1/2E[εR{S − ξ∗TZ(γ0)}] + bE[S{RS + (1−R)ξ∗TZ(γ0)}],
where ε = Y − γT0X − βnS. The first expectation on the far right side of the above expression is
E[εI{(Y, X̃) ∈ Ω(ω)}{S − ξ∗TZ(γ0)}]
= E[ε{S − ξ∗TZ(γ0)}P{(Y, X̃) ∈ Ω(ω) | ε, S,Z(γ0)}]






P{(t+ γT0X + ε, X̃) ∈ Ω(ω) | ε,γT0X, X̃}|t=0
]
+ o(1).















Simple algebraic manipulation yields n−1/2E{
∑n






= n1/2E[I{(Y, X̃) ∈ Ω(ω)}{S − ξ∗TZ(γ0)}Z(γ0)]




P{(t+ γT0X + ε, X̃) ∈ Ω(ω) | γT0X, X̃}|t=0S{S − ξ∗TZ(γ0)}Z(γ0)
]
≡ bµξ.






Because the conditional distribution of S given Z(γ0) may be misspecified, {S − ξ∗TZ(γ0)} in
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`ξ,i(γ0, ξ∗) is generally dependent of Z(γ0). Thus, the non-centrality parameter is a function of high
moments of Z(γ0), and it is difficult to evaluate the power for different choices of Z(γ0). Consider the
case that S is missing completely at random. In this case, Iβγ = −E[{RS + (1−R)ξ∗TZ(γ0)}XT],
and Iβξ = 0. The denominator of C is
Var(`β,i − IβγI−1γγ `γ,i)
= E[ε2{RS + (1−R)ξ∗TZ(γ0)− IβγI−1γγX}2]
= σ2E{RS + (1−R)ξ∗TZ(γ0)− E[{RS + (1−R)(ξ∗TZ(γ0)}X]E(XXT)−1X}2
= σ2E[P⊥X{RS + (1−R)ξ∗TZ(γ0)}]2,
where P⊥X denotes the projection onto the orthogonal space ofX, i.e., P⊥XT = T −XTE(XXT)−1×
E(XT ) for any random variable T . The numerator of C is
b2(µβ − IβγI−1γγµγ)2
= b2(E{RS2 + (1−R)Sξ∗TZ(γ0)} − E(SXT)E(XXT)−1E[{RS + (1−R)ξ∗TZ(γ0)}X])2
= b2(E[R{S2 − E(SXT)E(XXT)−1XS}
+(1−R){Sξ∗TZ(γ0)− E(SXT)E(XXT)−1Xξ∗TZ(γ0)}])2
= b2[pRE(P⊥XS)2 + (1− pR)Cov{P⊥XS,P⊥Xξ∗TZ(γ0)}]2
= b2[pRE(P⊥XS)2 + (1− pR)E{P⊥Xξ∗TZ(γ0)}2]2,
where pR = P (R = 1), and the last equality follows from the definition of ξ∗ and the fact that X is











To show that the proposed test is more powerful than the imputation score test without
stratification or the B-spline terms, we consider two sets of linear predictors Z1(γ̂) and Z2(γ̂),
where Z1(γ) is contained in Z2(γ). Let S̃1 and S̃2 be the imputed values of S using Z1(γ0) and
Z2(γ0), respectively. The score test with Z2(γ̂) in the imputation model is asymptotically more
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powerful if and only if




XS)2 + (1− pR)E(P⊥X S̃1)2]2
E[P⊥X{RS + (1−R)S̃1}]2
. (3.6)
After some algebraic manipulation, the denominator on the left side of (3.6) can be expressed as
pRE(P⊥XS)2+(1−pR)E(P⊥X S̃2)2+pR(1−pR){E(SXT)−E(S̃2XT)}E(XXT)−1{E(SX)−E(S̃2X)}.
Compared to S̃1, S̃2 is the projection of S onto a larger linear space. Thus,
{E(SXT)− E(S̃2XT)}E(XXT)−1{E(SX)− E(S̃2X)}
≤ {E(SXT)− E(S̃1XT)}E(XXT)−1{E(SX)− E(S̃1X)},
and E(P⊥X S̃2)2 ≥ E(P⊥X S̃1)2. It follows that (3.6) holds, and the test with a larger set of covariates
in the imputation is more powerful.
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CHAPTER 4
SURVIVAL TIME PREDICTION WITH MULTI-PLATFORM
HIGH-DIMENSIONAL GENOMIC DATA
4.1 Introduction
Prediction of disease outcomes, such as individual patient survival time, is critically important
for cancer patients. Traditional prognostic models that rely solely on clinical variables, such as
age and tumor stage, fail to account for the molecular features of tumors and thus may lead to
suboptimal treatment decisions (Shedden et al. 2008). To remedy this situation, many studies have
incorporated gene expression data for survival prediction (West et al. 2001; Beer et al. 2002; Shipp
et al. 2002; van’t Veer et al. 2002).
Large-scale genomics projects, such as The Cancer Genome Atlas (TCGA), have generated
detailed molecular data on patients with a variety of cancer types. In TCGA, six different types
of genomic data have been collected on patients: DNA copy number variation, DNA somatic
mutation, mRNA expression, miRNA expression, DNA methylation, and the expression of ∼200
proteins/phosphoproteins. The availability of different data types has enabled researchers to address
a variety of important questions. For example, patients can be more precisely classified into molecular
subtypes based on integrative clustering of multiple genomic data types or platforms (Shen et al.
2009; Mo et al. 2013; Lock et al. 2013). In addition, it is possible to identify genes that are related to
patient survival time by decomposing the expression of each gene into a component that is explained
by the methylation level and a component that is not (Wang et al. 2013).
One unsolved issue in cancer genomics is the prognostic value of integrated genomic and clinical
data versus clinical data only. Yuan et al. (2014) compared models with clinical data only versus
models with both clinical and genomic data on various cancer types and concluded that genomic
data provide only a limited gain in survival prediction accuracy. In their analysis, however, potential
differences among data types were not taken into account. For breast cancer, for instance, the
combination of genomic and clinical data does improve outcome predictions (Parker et al. 2009; Fan
et al. 2011). One of the goals of the present work is to more fully explore the predictive power of
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integrating clinical and genomic data together.
The second issue that we wish to address is the prognostic value of individual gene expression
data (∼12,000) versus a predefined set of gene expression signatures, which are also referred to
as “modules” (∼500). Gene modules represent activated molecular signaling pathways or specific
biological processes, and they have been developed to better capture signaling pathway activity or
cell type heterogeneity within tumors. We wish to investigate whether individual gene expression
data or existing gene modules provide more accurate outcome prediction.
A third issue is the relative importance of different types of genomic data in outcome prediction.
Different data types are collected at different costs and also with widely varying feature spaces.
Naturally, not all data types are equally important in outcome prediction. We aim to determine
which data types may be omitted from analysis without a significant reduction in prediction accuracy.
The overarching methodological challenge that we address in this chapter is the identification of
genomic variables predictive of survival time or other clinical outcomes when the number of variables
is much larger than the sample size. Penalization methods, such as least absolute shrinkage and
selection operator (LASSO) (Tibshirani 1996) and elastic net (Zou and Hastie 2005), are commonly
used to identify important genomic variables. Elastic net is preferable to LASSO because it better
handles highly correlated variables (Zou and Hastie 2005). However, both LASSO and elastic net
are generic variable selection procedures that do not distinguish different types of data. It is highly
desirable to account for differences in predictive power and the number of features of different data
types.
An alternative to penalization-based variable selection methods is boosting (Bühlmann 2006;
Bühlmann and Yu 2006). Boosting originated from a machine-learning context for classification
problems (Freund and Schapire 1996), which is not a separate classification procedure but is a
method to improve existing procedures. Specifically, boosting combines many “weak” classifiers
to obtain a much “stronger” classifier by repeatedly fitting the weak classifier and reweighting the
samples based on the results of the previous fit. Over the years, boosting has been generalized
to a much broader statistical framework that accommodates continuous, binary, and censored
outcomes; see Hastie et al. (2009) for the development of boosting. The main advantage of boosting
is that it can incorporate general simple estimation procedures, such as component-wise least-square
regression and classification tree, with stable computation. Boosting is typically performed with
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repeating a classification/prediction procedure on the same set of data, and boosting with different
data types treated separately in a variable-selection context has not been explored.
In this chapter, we develop a novel method, termed Integrative Boosting (I-Boost), that combines
elastic net with statistical boosting. The I-Boost approach considers each data type separately, so
that small but predictive data types will not be dominated by larger ones. Herein, we evaluate
I-Boost using simulation studies and data from the TCGA on patients with eight different cancer
types, namely colon adenocarcinoma (COAD), rectal adenocarcinoma (READ), lung adenocarcinoma
(LUAD), lung squamous cell carcinoma (LUSC), bladder urothelial carcinoma (BLCA), breast
invasive carcinoma (BRCA), kidney renal cell carcinoma (KIRC), and head and neck squamous cell
carcinoma (HNSC). We show that I-Boost outperforms LASSO and elastic net in terms of survival
prediction. We also demonstrate that when I-Boost is applied to integrated genomic and clinical
datasets, the accuracy of prediction is improved in comparison to that achieved with the use of a
single data type.
In Chapter 4.2, we review LASSO and elastic net and present the I-Boost procedure. In Chapter
4.3, we report results from simulation studies that compare the proposed and existing penalization
methods. In Chapter 4.4, we present results from the analyses of the TCGA dataset and address
the aforementioned three issues. We make some concluding remarks in Chapter 4.5 and provide
details about the TCGA data in Chapter 4.6.
4.2 Methods
4.2.1 LASSO and Elastic Net
Both LASSO (Tibshirani 1996) and elastic net (Zou and Hastie 2005) are penalized estimation
procedures; LASSO is a special case of elastic net. The elastic net estimator for the Cox proportional














where β = (β1, . . . , βp)T is a vector of regression parameters, L is the partial likelihood, λ and α
are tuning parameters, and p is the number of covariates. The objective function for LASSO is the
above expression with α = 1. With α = 0, elastic net reduces to ridge regression. For large values
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of λ, the penalty term dominates, and the parameter estimates tend to be small with some values
being exactly zero. Unlike LASSO, elastic net exhibits the grouping effect in that the regression
parameters for a group of highly correlated variables tend to be equal, which is desirable in the
context of gene selection.
The tuning parameters α and λ are typically selected by K-fold cross-validation. Cross-validation
was suggested by the authors of LASSO and elastic net (Tibshirani 1996; Zou and Hastie 2005).
In a K-fold cross-validation procedure, the dataset is randomly split into K subsets of equal size.
Each training set is a combination of (K − 1) subsets, and the corresponding testing set is the
remaining subset. For each set of tuning parameters, LASSO or elastic net is performed on all
training sets, and the resulting estimates are evaluated on the corresponding testing sets. We set
the cross-validation error associated with each set of tuning parameters to be the average deviance
based on the partial likelihood over all testing sets. The set of tuning parameters with the least
cross-validation error is chosen for the analysis on the whole dataset.
4.2.2 I-Boost
Let T be the survival time of interest, C be the censoring time, Y ≡ min(T,C) be the observed
survival or censoring time, and ∆ ≡ I(T ≤ C) be the event indicator, where I(·) is the indicator
function. Let X ≡ (X(1)T, . . . ,X(K)T)T be the set of predictors, where X(k) is a pk-vector that
contains predictors for the kth data type for k = 1, . . . ,K, and K is the total number of data types.
The observed data consist of (Yi,∆i,Xi) for i = 1, . . . , n.
The I-Boost algorithm is given as follows:
1. Set f0,i = 0 for i = 1, . . . , n, and let f0 = (f0,1, . . . , f0,n)T.
2. Consider m = 1, 2, . . .:
(a) For k = 1, . . . ,K, calculate
β(k) = argmaxβ
{
logL(k)n (fm−1;β)− p(k)(β;α, λ)
}
using the coordinate-descent method (Simon et al. 2011), where









is the partial likelihood with offset term f and covariates X(k), f = (f1, . . . , fn)T, and










is the elastic net penalty.
(b) Let k∗ = argmaxk logL
(k)
n (fm−1;β(k)).
(c) Set fm,i = fm−1,i + vX(k
∗)T
i β
(k∗) for i = 1, . . . , n and some fixed 0 < v ≤ 1 and
fm = (fm,0, . . . , fm,n)T.
At the kth iteration, the current estimate vβ(k∗) contributes to the final parameter estimate additively.
The final parameter estimate for each data type is simply the sum of the current estimates obtained
across all steps in which the data type achieves the maximum at step 2(b).
We propose two versions of I-Boost, with different methods for selecting the tuning parameters α
and λ at step 2(a). For I-Boost-CV, we adopt a two-dimensional five-fold cross-validation separately
at each iteration. To keep the update at each iteration small, we restrict the search of λ on a set of
large values. This results in small estimates and also a large number of parameters being shrunk to
zero. We set v = 1 at step 2(c).
For I-Boost-Permutation, we adopt the permutation method proposed by Sabourin et al. (2015).
The procedure is motivated by the principle that in a null model, i.e., in the absence of any relevant
predictors, the tuning parameters should be chosen such that no variable is selected. The permutation
selection procedure generates hypothetical null models by randomly permuting (Yi,∆i, fm−1,i) B
times, so that in each permutation dataset the association between the predictors and the outcome
(and the offset term) is removed. For each permutation, we fix α = 1 and find the smallest λ such
that no variable is selected. The selected λ for that iteration is the median of the B values of λ. We
set v = 0.1 at step 2(c).
Conventional boosting methods require a stopping criterion to avoid over-fitting. In our
experience, however, because the tuning parameters are selected separately at each iteration
for the two procedures, they eventually lead to shrinkage of all (current) parameter estimates.
Therefore, we do not adopt a separate procedure to determine the stopping time of the iteration.
We terminate the iteration when fm remains constant for five consecutive iterations.
4.3 Simulation Studies
We used the R-package “sampling” (Tillé and Matei 2016) to sample 500 subjects who had
complete data from the TCGA pan-cancer data set, balancing the clinical variables between the
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sampled and non-sampled subjects; see Chapter 4.6 for a description of the data. The outcome
variable was generated from a proportional hazards model with clinical variables, gene modules,
copy number data, miRNA expression, protein expression, and somatic mutation data as predictors.
The censoring time was generated to be independent of the predictors and survival time, with a
censoring proportion of approximately 65%.
The regression parameters were chosen to result in different proportions of signals across data
types, where the signal of data type k is defined to be Var(X(k)Tβ(k)0 ), β
(k)
0 is the true regression
parameter value, and the predictors were standardized. The variables with non-zero regression
parameters, hereafter referred to as signal variables, were chosen to be weakly correlated. We
considered three settings, with the distributions of signals and number of signal variables shown
in Figure 4.1. In Setting 1, the clinical variables contain much stronger signals than the other
data types. The miRNA and protein variables do not contain any signal. In Setting 2, the clinical
variables contain the most signals, and the remaining signals are evenly distributed across the other
data types. In Setting 3, the clinical variables contain the most signals, the modules and copy
number variables contain the second largest amount of signals, and the protein variables do not
contain any signals. In all three settings, the number of signal variables is less than 4% of the total
number of variables.
We evaluated the performance of LASSO, elastic net, and the two versions of I-Boost. Five-fold
cross validation was used to select the tuning parameters for LASSO and elastic net. For elastic
net, the cross-validation was performed over a two-dimensional grid of (α, λ), while for LASSO, we
set α = 1. The grid for α for elastic net was chosen to be (0.05, 0.1, 0.2, . . . , 1.0), and a grid for λ
was chosen separately for each α. To make the selection procedure more stable, we repeated the
split and evaluation procedure five times, and the cross-validation errors were averaged over the five
repetitions.
We assessed the performance of the methods by the quality of variable selection and prediction.
For variable selection, we report the false discovery rate. Because elastic net tends to select variables
that are highly correlated, we considered the selection of a variable that is highly correlated with any
of the signal variables (with absolute correlation greater than or equal to 0.6) as a “true discovery”,
so as not to bias against elastic net. For each selected variable, we calculated the maximum of the
absolute correlation between the selected variable and the signal variables, and we report the mean
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of the maximum absolute correlation over all selected variables. We call this measure the mean
correlation.










0 , where β̂
(k) is the estimated parameter vector. A higher
correlation represents a larger degree of agreement between the predicted and actual outcomes. We
call this assessment method the risk correlation.
The performance of elastic net, LASSO, and the two versions of I-Boost based on 1,000 replications
is shown in Figure 4.1. We also present the average number of variables selected for each method.
The simulation results show that, on average, elastic net selects the largest number of variables,
followed by I-Boost-CV, LASSO, and I-Boost-Permutation. In all settings, I-Boost-Permutation has
the lowest false discovery rate and selects variables that are, on average, most strongly correlated
with the signal variables.
For prediction, the two I-Boost methods perform the best overall. In Settings 1 and 2, where
the clinical variables contribute a large proportion of signals, the I-Boost methods produce more
accurate prediction than both elastic net and LASSO. In Setting 3, I-Boost-CV performs similarly
to elastic net, while LASSO performs worse than both versions of I-Boost. Between the two versions
of I-Boost, I-Boost-CV tends to yield better prediction than I-Boost-Permutation, possibly because
of the larger number of variables selected by I-Boost-CV. Thus, if the main interest is the selection
of relevant variables, then one might consider I-Boost-Permutation for more conservative variable
selection, even though this method is somewhat inferior in prediction when compared to I-Boost-CV.
4.4 Data Analysis Results
4.4.1 Evaluation of LASSO, Elastic Net, and I-Boost Using TCGA Data
We evaluated the performance of the analysis procedures using three TCGA datasets, namely,
the LUAD dataset, the KIRC dataset, and the pan-cancer dataset derived from more than 1,400
patients with one of eight different tumor types; see Chapter 4.6 for a description of the data. To
assess an analysis procedure, we split the data into multiple training and testing sets with a 3:2
ratio of sample sizes. We used the R-package “sampling” (Tillé and Matei 2016) to balance the data
split on the clinical variables. We performed the analysis on the training sets, and the results were
















































































































































Figure 4.1. Simulation Settings and Results: (a) Performance of LASSO, Elastic Net, I-Boost-CV,
and I-Boost-Permutation, in Terms of Number of Variables Selected, False Discovery Rate, Mean
Correlation, and Risk Correlation Under Three Different Settings; and (b) Number of Signal Variables
and Distribution of Signals Across Different Data Types for the Three Simulation Settings. The
number of signal variables is zero if the proportion of signals of the data type is 0%. Abbreviations
are as follows: GeneExp represents raw gene expression; Module represents gene module; Clinical
represents clinical variable; CNV represents copy number variant; Mutation represents somatic
mutation; miRNA represents micro-RNA expression; and Protein represents protein expression.
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D’Agostino 2004) on the testing set with β = β̂, where β̂ is the parameter estimate obtained from
the training set. In the case of no variable being selected, a C-index value of 0.5 was assigned. For
each split of the data, we repeated this estimation-validation procedure on different combinations of
data types as predictors. From the seven available data types, we formed 95 unique combinations of
data types. (Raw gene expression and gene modules did not enter the same model.) Finally, the
analyses were conducted on the multiple splits of the data and on the 95 combinations of data types
for the LUAD, KIRC, and pan-cancer datasets.
The average C-index values over the splits obtained from LASSO and elastic net are given in
Figures 4.2–4. For the analyses of the pan-cancer and KIRC datasets, the prediction tends to be
much better than random guessing, i.e., the C-index values are much larger than 0.5. In the analyses
of the LUAD dataset, which has smaller sample size, some of the C-index values are close to or only
slightly larger than 0.5.
For many models, the predictive performance of elastic net is either similar or superior to LASSO.
The tuning parameter α was selected to be smaller than 0.5 for over 70% of the time using the
cross-validation procedure. For approximately 15% of the time, α = 1 was selected.
For LASSO and elastic net, the models containing more data types as predictors do not necessarily
perform better than those with fewer data types. One possible explanation is that the extra data
types may contain very little relevant information on patient survival, such that adding those data
types introduces more noise into the model than signal. In practice, however, it is challenging to
decide which data types to consider without prior knowledge of their importance.
Figures 4.5–7 show the average values of the C-index obtained by I-Boost-CV and elastic net
for different models. For the LUAD and pan-cancer datasets, I-Boost provides better prediction in
many cases, especially for models that include clinical variables. This finding is consistent with the








































































































































































































































































































Figure 4.2. Analysis Results for the TCGA LUAD, KIRC, and Pan-Cancer Datasets, Using LASSO and Elastic Net for Models With Raw
Gene Expression Data. Each row represents a particular combination of data types used as predictors, as indicated by the box on the left.
Each dot is an average C-index value obtained by performing LASSO or elastic net on 30 training and testing dataset pairs. See the
































































































































































































































































































Figure 4.3. Analysis Results for the TCGA LUAD, KIRC, and Pan-Cancer Datasets, Using LASSO and Elastic Net for Models With
Gene Modules. Each row represents a particular combination of data types used as predictors, as indicated by the box on the left. Each dot
is an average C-index value obtained by performing LASSO or elastic net on 30 training and testing dataset pairs. See the caption of
























































































































































































































































































Figure 4.4. Analysis Results for the TCGA LUAD, KIRC, and Pan-Cancer Datasets, Using LASSO and Elastic Net for Models Without
Gene Expression Data. Each row represents a particular combination of data types used as predictors, as indicated by the box on the left.
Each dot is an average C-index value obtained by performing LASSO or elastic net on 30 training and testing dataset pairs. See the










































































































































































































































































































Figure 4.5. Analysis Results for the TCGA LUAD, KIRC, and Pan-Cancer Datasets Using Elastic Net and I-Boost-CV for Models With
Raw Gene Expression Data. Each row represents a particular combination of data types used as predictors, as indicated by the box on the
left. Each dot is an average C-index value obtained by performing elastic net or I-Boost-CV on 30 training and testing dataset pairs. See






































































































































































































































































































Figure 4.6. Analysis Results for the TCGA LUAD, KIRC, and Pan-Cancer Datasets Using Elastic Net and I-Boost-CV for Models With
Gene Modules. Each row represents a particular combination of data types used as predictors, as indicated by the box on the left. Each dot
is an average C-index value obtained by performing elastic net or I-Boost-CV on 30 training and testing dataset pairs. See the caption of































































































































































































































































































Figure 4.7. Analysis Results for the TCGA LUAD, KIRC, and Pan-Cancer Datasets Using Elastic Net and I-Boost-CV for Models
Without Gene Expression Data. Each row represents a particular combination of data types used as predictors, as indicated by the box on
the left. Each dot is an average C-index value obtained by performing elastic net or I-Boost-CV on 30 training and testing dataset pairs.




































































































































● Clinical only model using I−Boost−CV
Clinical only model using standard Cox regression
Figure 4.8. C-Index Values for the TCGA LUAD, KIRC, and Pan-Cancer Datasets, Using I-Boost-
CV for Models Containing Clinical Variables. Each dot represents the average C-index value obtained
by performing I-Boost-CV on a set of predictors that contains the clinical variables over 30 training
and testing dataset pairs. The average C-index values obtained by fitting I-Boost-CV or the standard
Cox regression on the clinical variables are marked.
To assess whether I-Boost captures useful information from the genomic variables beyond that
drawn from the clinical variables, we compared the values of the C-index obtained by I-Boost-CV
for all models that include the clinical variables. The plot of the C-index values is provided in
Figure 4.8. Because the standard maximum partial likelihood estimation is arguably preferable to
any regularized regression procedures in the model with clinical variables only, we also computed
the C-index from the standard analysis for that model. For the KIRC and pan-cancer datasets, the
majority of the models that contain both clinical and genomic variables provide better prediction
than either I-Boost or maximum partial likelihood estimation with clinical variables only. For the
LUAD dataset, only several models that contain both clinical and genomic variables provide better
prediction than the model with clinical variables only. These results indicate that genomic variables
contribute to survival prediction in the presence of clinical variables, and the magnitude of the
contribution can be large. However, when the same comparisons are made using LASSO or elastic
net, the inclusion of genomic variables in the models does not appreciably improve prediction.
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4.4.2 Evaluation of Signatures, Individual Genes, and Different Genomic Data Types
To compare the performance of gene modules versus individual gene expression data, we
calculated the C-index values for models with each data type separately. Specifically, for each
combination of data types besides individual gene expression data and gene modules, we computed
the difference between the C-index values obtained from I-Boost-CV on those data types with
gene modules and on those data types with gene expression data. The differences in the C-index
are shown in Figure 4.9. For the LUAD dataset, the use of gene modules mostly leads to better
prediction than the use of gene expression data of all individual genes. For the KIRC and pan-cancer
datasets, performance is similar with gene modules or individual gene expression data included in
the models.
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Figure 4.9. Comparison of C-Index Values for Models Containing Raw Gene Expression Data
and Models Containing Gene Modules Using the TCGA LUAD, KIRC, and Pan-Cancer Datasets.
Each dot represents the difference in average C-index values obtained by fitting I-Boost-CV on two
sets of predictors over 30 training and testing dataset pairs. The first set of predictors contains
a combination of data types and gene modules; the second set of predictors contains the same
combination of data types and raw gene expression data. A positive difference represents better
prediction using the model with gene modules.
To evaluate the relative importance of the data types, we constructed a series of nested models
as follows. First, we compared all models containing a single data type and selected the model that
was the most predictive. Then, we compared the models containing the selected data type and
another data type and again selected the most predictive model. This process was repeated until all
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data types were included, and the model selected at each step contained all of the previously selected
data types. Individual gene expression data were not considered in this analysis. The order that
the data types entered the models reflects their relative importance. We performed this procedure
for elastic net and the two versions of I-Boost. For the LUAD, KIRC, and pan-cancer datasets, the
C-index values for the series of models are plotted in Figure 4.10, and the data type selected at
each step is shown. We also plotted the average number of variables selected for each model.
For the LUAD, KIRC, and pan-cancer datasets, with the inclusion of each new data type under
I-Boost-Permutation, the C-index tends to increase or stay approximately the same. I-Boost-CV
yields results with similar patterns, although the C-index may decrease by a small amount as more
data types are included. This indicates that I-Boost extracts useful information from each additional
data type and that its performance tends not to be worsened by the inclusion of additional variables.
For the LUAD and pan-cancer datasets, clinical variables and gene modules are always the first data
types to be selected, and the improvement in prediction accuracy with the inclusion of additional
data types is marginal. For the KIRC dataset, miRNA expression data are the first to be selected
by elastic net and I-Boost-CV, while gene modules are first selected by I-Boost-Permutation. For
elastic net, there is no clear improvement in prediction accuracy when more data types are included.
In the LUAD, KIRC, and pan-cancer datasets, elastic net yields larger C-index values for models
with a single data type than I-Boost. This result is not surprising, because the main advantage of
I-Boost lies in the handling of multiple data types.
I-Boost-Permutation always selects the smallest number of variables, and I-Boost-CV selects the
second smallest number of variables in most cases. As more data types are included, the number of
variables selected by elastic net tends to fluctuate greatly, while the number of variables selected by
I-Boost tends to increase gradually. This suggests that the tuning parameter selection procedure
for I-Boost is more stable than that for elastic net. Because the C-index obtained by I-Boost is
higher in most cases than that obtained by elastic net, we conclude that I-Boost provides the same
or better prediction using fewer variables than elastic net.
To obtain a final set of important predictors, we performed I-Boost-Permutation on the LUAD,
KIRC, and pan-cancer datasets. We plotted the comparison of C-index values in Figures 4.11–13 and
demonstrate that I-Boost-Permutation yields comparable prediction accuracy to I-Boost-CV. The


























































































































































































































































































Figure 4.10. Analysis Results for the TCGA LUAD, KIRC, and Pan-Cancer Datasets, Using Elastic
Net, I-Boost-CV, and I-Boost-Permutation on Nested Models. For the plots on the left side, each dot
represents the average C-index value obtained by fitting elastic net or I-Boost-CV over 30 training
and testing dataset pairs. The leftmost dot represents the largest average C-index value among
models that contain one data type. Each of the other dots represents the largest average C-index
value among models that contain one more data type than the model corresponding to the dot on the
left. For the plots on the right side, the average number of selected variables for the models shown
on the left is plotted. For all plots, beside each dot, the name of the additional data type is included.



























































































































































































































































































Figure 4.11. Analysis Results for the TCGA LUAD, KIRC, and Pan-Cancer Datasets, Using I-Boost-CV and I-Boost-Permutation for
Models With Raw Gene Expression Data. Each row represents a particular combination of data types used as predictors, as indicated by
the box on the left. Each dot is an average C-index value obtained by performing I-Boost-CV or I-Boost-Permutation on 30 training and




























































































































































































































































































Figure 4.12. Analysis Results for the TCGA LUAD, KIRC, and Pan-Cancer Datasets, Using I-Boost-CV and I-Boost-Permutation for
Models With Gene Modules. Each row represents a particular combination of data types used as predictors, as indicated by the box on the
left. Each dot is an average C-index value obtained by performing I-Boost-CV or I-Boost-Permutation on 30 training and testing dataset























































































































































































































































































Figure 4.13. Analysis Results for the TCGA LUAD, KIRC, and Pan-Cancer Datasets, Using I-Boost-CV and I-Boost-Permutation for
Models Without Gene Expression Data. Each row represents a particular combination of data types used as predictors, as indicated by the
box on the left. Each dot is an average C-index value obtained by performing I-Boost-CV or I-Boost-Permutation on 30 training and
testing dataset pairs. See the caption of Figure 4.1 for the abbreviations of the data types.
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NOTE: “Estimate” is the estimate of the log hazard ratio under the Cox proportional hazards model, where a positive
value represents an increase of the hazard. The predictors are standardized to have unit standard deviation. Gender is
coded as female = 0 and male = 1; pathologic stage T is dichotomized into T1 (0) and T2-T4 (1); pathologic stage N
is dichotomized into N0 (0) and N1-N3 (1).
Age and pathological nodal status were selected as strong negative prognostic factors in the
analyses of the LUAD, KIRC, and pan-cancer data sets. Age has been reported to be associated
with prognosis for many cancer types (Lieu et al. 2014; de la Rochefordière et al. 1993; Asmis
et al. 2008). In the analysis of the pan-cancer dataset, indicators of the multiple cancer types
included in this dataset were selected, which is logical, since the survival time is known to depend
on cancer types (Hoadley et al. 2014); the tissue of origin is an important prognostic factor. Among
the gene modules, Glycolysis_signature and MUnknown_24 were selected as negative prognostic
factors in the LUAD and pan-cancer datasets; these two modules are correlated with Hypoxia
signatures (Pearson correlation = 0.59) among a set of 1,198 TCGA breast cancer samples. Likewise,
Pcorr_IGS_Correlation and Activate_Endothelium, which were selected as negative prognostic
factors for the pan-cancer dataset, were correlated with proliferation signatures (Pearson correlation
= 0.96); these features are robust negative prognostic factors.
In contrast, signatures of CD8 T cells, non-inflammatory breast cancer (nIBC and MM_Red2,
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Table 4.2. Analysis Results From I-Boost-Permutation for the TCGA KIRC Dataset.
Predictor Estimate
Protein_AR −0.1071
Module_IMMUNE_Bindea_Cell_CD8 T cells_Median_Immunity.2013_PMID.24138885 −0.0695
Module_Mature_LuminalUp_Median_Nat.Med.2009_PMID.19648928 −0.0675
Module_UNC_MM_Red2_Median_BMC.Med.Genomics.2011_PMID.21214954 −0.0662


























NOTE: See NOTE to Table 4.1.
103
Pearson correlation = 0.84), and luminal features (Mature_LuminalUp, HS_Green1, HS_Green8,
LUMINAL_Cluster, Duke_Module06_er, Pcorr_Dasatinib_L_Correlation, GP7_estrogen signal-
ing, and HS_Green18, Pearson correlation = 0.74) were selected as positive prognostic factors for the
KIRC or pan-cancer datasets. The NEU_cluster module was selected as a strong positive predictor
for the LUAD dataset, which is biologically significant because this module represents epithelial
luminal cell differentiation and thus tracks more differentiated and lower grade lung cancers. These
selected features, together with their biological implications, demonstrate the robustness of the
I-Boost methodology.
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NOTE: See NOTE to Table 4.1. For cancer type, BRCA is the reference group.
4.5 Discussion
In this chapter, we propose a novel method, termed I-Boost, for variable selection and outcome
prediction that is especially powerful when one wishes to consider multiple data types at once. We
used simulation studies and real-data analyses to demonstrate that in the presence of small but
predictive data types (such as clinical variables), I-Boost produces better outcome prediction than
LASSO and elastic net. In addition, I-Boost selects fewer variables than elastic net, which may
be preferable for follow-up experiments. Finally, I-Boost is less sensitive to the tuning parameter
selection procedure than elastic net.
Consistent with the current literature, we found that clinical variables are strong predictors of
survival time. With I-Boost, we were able to build upon the clinical variables and extract additional
useful information from genomic variables in order to improve the prediction; the improvement that
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we obtained with I-Boost was considerably larger than that obtained by either LASSO or elastic
net. We also compared the use of individual gene expression data versus gene modules and found
that the use of gene modules leads to similar or better prediction accuracy and more interpretable
results. When we considered the selected I-Boost models, clinical variables (e.g., age, tumor size,
and pathological nodal status) were strong predictors of survival. I-Boost also selected several gene
modules that were previously identified as prognostic of outcomes.
Our study has some limitations. The main limitation is that the LUAD and KIRC datasets
pertain to a relatively small number of patients, with an even smaller number of observed deaths.
This limitation motivated us to combine eight solid epithelial tumor types to form a large pan-cancer
dataset. The analyses on the pan-cancer data might not properly account for heterogeneity across
different cancer types. Another limitation of our study is that the quality of the clinical data differs
across different cancer types; for example, the follow-up time for some cancer types was quite short.
For all analyses performed herein, the outcome of interest was the overall survival time. It may
be preferable to use time-to-tumor progression as the outcome as it is more directly related to
the clinical and genomic predictors. In that case, I-Boost needs to be extended to accommodate
recurrent events, as a patient may experience multiple tumor progression events. Finally, the I-Boost
methodology is applicable to any disease states where multiple types of genomic data are available.
4.6 Detailed Data Description
Data on 2,272 TCGA samples representing the eight different cancer types listed in Chapter 4.1
were obtained from the December 22, 2012 Pan-Cancer-12 data freeze from the Sage Bionetworks
repository Synapse (https://www.synapse.org). We used the dataset that was previously processed
and described by Hoadley et al. (2014) for all data types except protein expression. The protein
data were downloaded from Broad GDAC Firehose (http://gdac.broadinstitute.org/) on June 26,
2017. In the analyses, COAD and READ were combined as one cancer type.
Clinical variables included gender, age, pathological stages T and N, and cancer type. For mRNA
expression data, we used RNA-seq by Expectation-Maximization (RSEM) (Li and Dewey 2011) to
quantify the transcript abundances measured by RNA sequencing and used the log2-transformed
up-quantile-normalized RSEM values of 12,434 genes. The RNA sequencing was performed at
the University of North Carolina at Chapel Hill (The Cancer Genome Atlas Research Network
2012a;b;c). Gene level expression data are also available on the TCGA Data Portal (https://tcga-
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data.nci.nih.gov/tcga/). For mutation data, we used the single nucleotide variant calls, which
were de-duplicated and re-annotated using the ENSEMBLE version 69 transcript database. A
total of 130 genes with non-synonymous mutations in more than 10% of the whole sample were
included for the analyses. The combined mutation annotation format file is available from the
Synapse resource. For miRNA expression data, we used the read count data for 305 normalized
expressions, which were compiled into an abundance matrix for 5p and 3p mature miRBase strands,
as described by The Cancer Genome Atlas Research Network (2012c). For reverse-phase protein
arrays, we used the level-3 normalized data for 136 proteins or phospho-proteins.. For copy number
data, SNP6.0 array-based gene-level somatic copy number alteration data were generated from the
GISTIC analysis (Zack et al. 2013). The input data matrix is available in Synapse at syn1710678.
We used the copy number values for 216 cancer-specific segments, which are frequently aberrated in
cancer of various types including breast cancer, and segments for all chromosome arms (a total of
41 segments) (Beroukhim et al. 2010; Chao et al. 2012).
We defined gene modules as sets of co-expressed genes that are considered to be functional units
in breast cancer. We built a collection of 504 gene modules. The modules were constructed based
on 73 publications or results from the Gene Set Enrichment Analysis (Subramanian et al. 2005).
A partial list of the modules appears in Fan et al. (2011). Among the modules, 468 are median
expression values for homogeneously expressed genes, 33 are correlations of expression values with
predetermined gene centroids, and 3 are built from previously published gene expression prognostic
models.
After removing patients with missing data, the total sample size was 1,420, including 202 LUAD
samples and 195 KIRC samples. All survival times were censored at five years if the patients were
still in the study at that time point. For the pan-cancer dataset, the median follow-up time was
16.8 months, and the censoring proportion was 77.6%. For the LUAD dataset, the median follow-up
time was 13.9 months, and the censoring proportion was 71.3%. For the KIRC dataset, the median
follow-up time was 28.9 months, and the censoring proportion was 63.6%.
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CHAPTER 5
FUTURE WORK — VARIABLE SELECTION WITH MISSING DATA IN
MULTI-PLATFORM GENOMICS STUDIES
5.1 Introduction
Most phenotypic variations of interest are not driven by the activities of a single gene but are the
products of many genes acting in concert with one another at multiple layers of genomic structures.
As a result, the marginal association of a certain feature of a gene with a phenotype may be quite
different from the actual relationship between the gene and the phenotype. Also, the predictive
power of a single gene is very low. It is therefore desirable to consider multiple types of genomic
variables of all genes in a single analysis framework.
A naïve approach to model a phenotype and multiple types of genomic variables is to regress
the phenotype on all genomic variables and model the relationships among each type of genomic
variable using standard regression techniques. However, this approach is infeasible because each
type of genomic variables is high-dimensional, and the number of parameters in the resulting model
is much larger than the sample size of any genomic studies. The problem is further complicated
by the presence of missing data. In a genomics study, due to cost constraints or other practical
reasons, not all study subjects are measured for all genomic variables. For example, in The Cancer
Genome Atlas (TCGA), protein expressions are only collected on a subset of subjects. Simple
methods for handling missing data, such as complete-case analysis and single imputation, inevitably
suffer efficiency loss and may even yield biased results. By contrast, the full-likelihood approach is
valid, but it involves integration over all missing variables and thus is computationally infeasible for
high-dimensional data.
In this chapter, we consider a high-dimensional regression model of a phenotype on multiple
types of partially missing genomic variables and a latent variable model for the genomic variables.
Under the proposed model, the likelihood function involves an integration of dimension that does
not depend on the dimension of the genomic variables but depends only on the number of latent
variables, which is chosen to be small. We develop a computationally efficient penalization EM
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algorithm for variable selection.
In Chapter 5.2, we formulate the problem and develop the penalized estimator. In Chapter 5.3,
we discuss the numerical implementation of the proposed estimator. In Chapter 5.4, we present
preliminary results on the theoretical properties of the proposed estimator and outline their proofs.
5.2 Methods
Consider a genomics study that involves a phenotype Y , a p-dimensional vector of binary genomic
variables G, and a q-dimensional vector of continuous genomic variables S. Both G and S may
include multiple types of genomic variables. We assume the model:
Y | (G,S) ∼ f(Y ;αTG+ βTS, ξ)
logit{P (Gj = 1 | U)} = θTj U∗ for j = 1, . . . , p
S = ΨU∗ + ε,
where f is a density function with nuisance parameter ξ, α and β are regression parameters,
U∗ = (1,UT)T, U is an r-dimensional multivariate standard normal latent variable, θj ∈ Rr+1 is a
vector of regression parameters, Ψ ∈ Rq×(r+1) is a matrix of regression parameters, ε = (ε1, . . . , εq)T,
and εk follows i.i.d. N(0, γ2k). Let Θ = (θ1, . . . ,θp)T. The models of G and S have been considered
by Shen et al. (2009) for classifying patients into subtypes using multi-platform genomic data.
We allow elements of G and S to be missing. Let Qj and Rj , by values 0 and 1, denote
whether Gj and Sj are observed, respectively, Q = (Q1, . . . , Qp)T, and R = (R1, . . . , Rq)T. The
observed data consist of (Yi,Qi ◦Gi,Ri ◦ Si,Qi,Ri) for i = 1, . . . , n, where ◦ denotes element-wise







f(Yi;αT{Qi ◦Gi + (1−Qi) ◦G}

























TU dε dU ,
where G = (G1, . . . , Gp)T, and ψTj is the jth row of Ψ.
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To estimate the parameters, we adopt a penalized-likelihood approach with an (adaptive) L1-
penalty on (α,β) and an L2-penalty on (Θ,Ψ). The penalized maximum likelihood estimator
ν̂ ≡ (α̂, β̂, ξ̂, Θ̂, Ψ̂) is
ν̂ = arg max
ν
{logL(ν)− λ1(|wα ◦α|+ |wβ ◦ β|)− λ2(‖Θ(−1)‖22 + ‖Ψ(−1)‖22)},
where γ = (γ1, . . . , γq)T, (Θ(−1),Ψ(−1)) is (Θ,Ψ) with the first columns removed, and wα and wβ
are vectors of weights for α and β, respectively. The weights wα and wβ consist of the inverse of the
absolute values of α̃j or β̃j , where α̃j and β̃j are some consistent estimators of αj and βj , respectively.
In practice, we may set α̃j and β̃j to be the L1- or L2-penalized maximum likelihood estimators or
the maximum likelihood estimators of the regression coefficients in the models f(Y ;αjGj ; ξ) and
f(Y ;βjSj ; ξ), respectively.
5.3 Computation of the Penalized Estimator
We propose a penalization EM algorithm for the computation of ν̂, with U and components
of ε that correspond to the missing components of S treated as missing data. For simplicity of
presentation, assume that G is observed for all subjects and S = (S(1)T,S(2)T)T, such that S(1) is
observed for all subjects, and S(2) is completely missing for some subjects. Let q1 and q2 be the
dimensions of S(1) and S(2), respectively, and partition β = (β(1)T,β(2)T)T, ε = (ε(1)T, ε(2)T)T, and




and Γ be an orthonormal matrix with the first row being ΓT1 . Define ε̃(2) = Γdiag(γ−1q1+1, . . . , γ
−1
q )ε(2),
such that ε̃(2)1 = c−1β(2)Tε(2). In terms of U and ε̃(2), the complete-data likelihood for the ith
subject is
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−1 follows the (q2 − 1)-dimensional multivariate
standard normal distribution, where ε̃(2)−1 is a vector of the last (q2−1) elements of ε̃(2). The posterior
expectation of any function of U can be calculated by numerical integration over (U , ε̃(2)1 ), instead
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of the whole set of high-dimensional missing data.
Upon calculation of the weights wα and wβ, the penalization EM algorithm iterates over the
following steps until convergence:
1. For each subject, obtain the weights for the Gauss-Hermite quadrature for the conditional
expectation of any function of U . Calculate the first and second moments of (U , ε̃(2)1 )
conditional on the observed data, and use them to obtain the first and second conditional
moments of (U , ε(2)). Let Ê be the conditional expectation with respect to (U , ε(2)).
2. For j = 1, . . . , p, maximize
n∑
i=1




i )} − λ2‖θ(−1)j ‖
2
2
using the Newton-Raphson algorithm, where θ(−1)j is θj with the first element removed.












at the current estimate of γ2j , where ψ
(−1)
j is ψj with the first element removed. A closed-form
solution is available for ψj . Then, estimate γ2j using the empirical sum of squares.
4. Let S̃i = Ri ◦Si + (1−Ri) ◦ (ΨU∗i + εi), where Ψ is evaluated at the estimate from step (3).















−λ1σ2(|wα ◦α|+ |wβ ◦ β|)
using the “covariance-updates” algorithm of Friedman et al. (2010), where µ and σ2 are the
intercept and error variance, respectively. Then, update µ and σ2 using the closed-form
solutions.
5. For the generalized linear model or Cox proportional hazards model, replace the log-density
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function of the phenotype in the log-likelihood function by a quadratic approximation (Friedman




wiÊ{(zi −αTGi − βTS̃i)2} − λ1(|wα ◦α|+ |wβ ◦ β|)
for some (w1, . . . , wn) and (z1, . . . , zn) that do not depend on α and β. We can then update
α and β using the covariance-updates method of step (4). Finally, update the nuisance
parameters of the phenotype model using the Newton-Raphson algorithm or a closed-form
solution, if available.
5.4 Preliminary Theoretical Results
In this section, we establish the theoretical properties of the proposed estimators under some
rather restrictive settings. With an abuse of notation, let θ denote the collection of all Euclidean
parameters and η denote the collection of all infinite-dimensional parameters. Let Pn be the
empirical measure and P be the true probability measure. Let `(θn,η) be the log-likelihood function
for one subject at (θn,η), so that nPn`(θn,η) is the log-likelihood function of a sample of size
n, and p`n(θn) ≡ nmaxη Pn`(θn,η) is the profile log-likelihood. (We index θ by the sample size
n, such that the number of parameters may increase with the sample size.) To simplify notation,
let βn ∈ Rp1n denote the regression parameters of (G,S), ψn ∈ Rp2n denote the collection of
regression parameters in the models of G and S, ξn denote the remaining Euclidean parameters,





n0 )T, where the components of β
(1)
n0 are non-zero, β
(2)
n0 = 0, and β
(1)
n0 is of dimension
sn. Let pn be the dimension of θn. The estimator θ̂n maximizes the following penalized (profile)
log-likelihood:
Φn(θn) ≡ p`n(θn)− nλ1n
p1n∑
j=1




where wnj = |β̃nj |−1, and β̃nj is an initial estimator of βnj . Assume that:
(C1) The initial estimator β̃nj = Op(n−τ ) for sn < j ≤ p1n and some τ ≤ 12 , and |β̃nj | > C0 > 0
(1 ≤ j ≤ sn) for large enough n and some constant C0.
(C2) Each element of θn belongs to some bounded subset of R.
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(C3) The tuning parameter λ1n = o(p−3/2n s−1/2n ) and λ2n = o(p−3/2n p−1/22n ).
(C4) The number of parameters pn = o(n1/4).
Following Murphy and van der Vaart (2000), we assume the existence of an “approximately
least-favorable submodel”. For any fixed (θ,η), let t 7→ ηt(θ,η) be a map from the parameter
space of θ into the parameter space of η. Let l(t,θ,η) = `(t,ηt(θ,η)), such that l is three-times
continuously differentiable almost surely with respect to the first component, and l(1), l(2), and l(3)
denote its the first, second, and third derivatives, respectively. The approximately least-favorable
submodel satisfies the following conditions:
(C5) For every (θn,η), ηθn(θn,η) = η.
(C6) The first derivative l(1)(θn0,θn0,η0) = ˜̀n(θn0,η0), where ˜̀n(θn0,η0) is the efficient score
statistic of θ.
(C7) For any random sequence θ̃n such that ‖θ̃n − θ0‖ = Op(
√
pn/n), η̂θ̃n →p η0, where η̂θ̃n =
arg maxη Pn`(θ̃n,η).
(C8) The efficient information matrix Ĩn(θn0,η0) ≡ P ˜̀n(θn0,η0)˜̀n(θn0,η0)T = P∂˜̀n(θn0,η0)/∂θn0,
with 0 < C1 < λmin{Ĩn(θn0,η0)} ≤ λmax{Ĩn(θn0,η0)} < C2 <∞ for all n and some constants
C1 and C2, where λmin(A) and λmax(A) denote the smallest and largest eigenvalues of a
matrix A. The derivatives of l satisfy
|P l(1)(θn0, θ̃n, η̂θ̃n)|
+|(Pn − P ){l(1)(θn0, θ̃n, η̂θ̃n)− l
(1)(θn0,θn0,η0)}| = op(‖θ̃n − θn0‖+ n−1/2)
‖Pnl(2)(θn0, θ̃n, η̂θ̃n)− Pnl
(2)(θn0,θn0,η0)‖ = Op(‖θ̃n − θn0‖)
P{l(1)j (θn0,θn0,η0)l
(1)
k (θn0,θn0,η0)} < C3 <∞
P{l(2)jk (θn0,θn0,η0)
2} < C4 <∞,
for some positive constants C3 and C4, and |l(3)jkh(θn0,θ,η)| is bounded above by a random
variableM for all values of (θ,η) in the parameter space, where E(M2) < C5 <∞ for some
positive constant C5.
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We have the following result.
Theorem 5.1. Under conditions (C1)-(C8), there exists a local maximizer θ̂n of Φn(θn) such that













p2nλ2n. It is sufficient to prove that for any





Φn(θn0 + αnu) < Φn(θn0)
}
> 1− ε,
i.e., for any n, there exists a local maximum of Φn in the Cαn-neighborhood of θn0 with probability
1− ε. Let
Dn(u) = Φn(θn0 + αnu)− Φn(θn0)




wj(|βn0j + αnuβj | − |βn0j |)− nλ2n
p2n∑
j=1
{(ψn0j + αnuψj)2 − ψ2n0j}, (5.2)
where (uβ1, . . . , uβp1n) and (uψ1, . . . , uψp2n) are elements of u corresponding to βn and ψn, respec-
tively. Let θ̃n = θn0 + αnu. The difference of the first two terms on the right-hand side of (5.2)
is
p`n(θ̃n)− p`n(θn0) = nPn`(θ̃n, η̂θ̃n)− nPn`(θn0, η̂θn0)
≤ nPn`(θ̃n,ηθ̃n(θ̃n, η̂θ̃n)− nPn`(θn0,ηθn0(θ̃n, η̂θ̃n))
= nPnl(θ̃n, θ̃n, η̂θ̃n)− nPnl(θn0, θ̃n, η̂θ̃n),
where the inequality follows because, by condition (C5), the first term is unchanged, and the second
term is reduced by replacing η̂θn0 by ηθn0(θ̃n, η̂θ̃n). By the Taylor’s series expansion at the first
argument of l, the above is equal to
n(θ̃n − θn0)TPnl(1)(θ0, θ̃n, η̂θ̃n) +
n
2 (θ̃n − θn0)
TPnl(2)(θ0, θ̃n, η̂θ̃n)(θ̃n − θn0)
+n6 {(θ̃n − θn0)
TPnl(3)(θ0,θ∗n, η̂θ∗n)(θ̃n − θn0)
T}(θ̃n − θn0), (5.3)
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where θ∗n is some value between θn0 and θ̃n. The first term of (5.3) is equal to
n(θ̃n − θn0)TPnl(1)(θ0, θ̃n, η̂θ̃n)
= n(θ̃n − θn0)T(Pn − P )l(1)(θ0, θ̃n, η̂θ̃n) + n(θ̃n − θn0)
TP l(1)(θ0, θ̃n, η̂θ̃n)





‖Pnl(2)(θ0, θ̃n, η̂θ̃n)− Pnl
(2)(θ0,θ0,η0)‖ = Op(p3/2n )αn‖u‖.
Also, for any ε > 0
P
(
















where the last line follows from condition (C8) and the dominated convergence theorem. Therefore,









T{Pnl(2)(θ0, θ̃n, η̂θ̃n)− Pnl













n λ1n + p3/2n p1/22n λ2n → 0 by








∣∣α3n ≤ Op(p3/2n αn)nα2n‖u‖2 = op(nα2n)‖u‖3.
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The forth term of (5.2) is bounded above by
Op(nλ2nαn
√
p2n)‖u‖+ nλ2nα2n‖u‖2 = Op(nα2n)‖u‖+ op(nα2n)‖u‖2.







which is negative for large enough C. The desired result follows.
By Theorem 5.1, if we choose λ1n = O{
√
pn/(snn)} and λ2n = O{
√
pn/(p2nn)}, then condition
(C3) is satisfied, and θ̂n converges at rate
√
n/pn. Variable-selection consistency is given by the
following result.




pn →∞, and the conditions of Theorem
5.1 hold, then with probability tending to 1, there exists a local maximum of Φn(θn), θ̂n, with β̂n
such that β̂n0j 6= 0 for j ≤ sn, and β̂n0j = 0 for j > sn.
Proof of Theorem 5.2. First, we prove that β̂n0j = 0 for j > sn. In light of Theorem 5.1, it suffices
to prove that for any ‖β(1)n − β
(1)
n0 ‖+ ‖ψn −ψn0‖+ ‖ξn − ξn0‖ = Op(
√
pn/n) and any constant C,




Φn{(β(1)Tn ,β(2)Tn )T,ψn, ξn},
or, equivalently, that ∂Φn(θn)/∂β(2)nj and β
(2)






















(θnk − θn0k)− nλ1nw2jsgn(β
(2)
nj ).
Under regularity conditions, we can show that the first two terms on the right-hand side of the
above equation is Op(
√
npn). Therefore, the above equation is
−n1+τλ1nn−τw2jsgn(β(2)nj ) +Op(
√












|β̂nj | ≥ min
j≤sn
|βn0j | − ‖β̂n − βn0‖
= λ1nn−τ












which is strictly positive for large enough n. Therefore, β̂n0j 6= 0 for j ≤ sn.
If we can find an nτ -consistent estimator of βn and choose λ1n = O{
√
pn/(nsn)} and λ2n =
O{
√
pn/(np2n)}, then the adaptive LASSO estimator is consistent and selects all and only the
relevant covariates asymptotically. It remains to find the estimator of βn. A possibility is to use








By the same arguments as the proof of Theorem 5.1, ‖β̃n − β̃n0‖ = Op(
√
pn/n), if λ̃1n =
O{
√
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